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CD8+ T cells are important for resolving attacks by pathogens such as viruses 
and parasites. Recently, transnuclear mice monoclonal for each of three TCRs 
recognizing the Rop7 antigenic peptide from the parasite Toxoplasma gondii 
were generated. To better understand T cell immunity against the parasite, I 
characterized the binding affinities of these three T Cell Receptors (TCRs) 
against the Rop7 peptide MHC molecule. I observed a range of binding 
affinities for these three TCRs. Moreover, binding kinetic studies also 
revealed that they contact the peptide Major Histocompatibility Complex 
(pMHC) for different periods of time. These data indicate that during an 
infection by the parasite, T cells expressing TCRs with a range of binding 
affinities are activated. Thus, T cell activation is not solely dependent on the 
binding affinity of the TCR to its cognate ligand. 
 
With the soluble TCRs generated from the binding affinity and kinetics 
studies, I sought to increase the stabilities of soluble TCRs so as to increase 
their attractiveness as a potential alternative immunoconjugate platform to 
monoclonal antibodies. To this end, I selected the Rop7c1 TCR, which has the 
highest refolding yield as well as binding affinity, to try and improve its 
stability. Increasing the surface charges of a protein have been shown to 
increase the thermostabilities of some proteins. Thus, I increased the surface 
charges of the Rop7c1 TCR by selecting and mutating highly surface exposed 
residues to either positively or negatively charged residues. However, 
increasing the surface charges did not improve the stability of the TCR. 
 VIII	  
Several factors such as free energy and surface charge-charge interactions play 
a role in protein stability as well and thus, solely increasing the surface 
charges of the TCR may not be sufficient to improve its stability. 
 
With our collaborator’s data, I was also able to compare the binding affinities 
of the three TCR clones with the effector function of the T cells expressing 
them. I observed that the binding affinities of the TCR do not correlate 
positively with the strength of their effector function. This implies T cell 
effector function may not be dependent on TCR binding affinity but on other 
possible intrinsic factors. More experiments will be required to identify these 
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Chapter 1: Introduction 
 
Pathogens in our environment are constantly evolving, trying to evade host 
defence mechanisms and looking for opportunities to infect us. The adaptive 
immunity plays a huge role in protecting us against such microbial attacks. Its 
arsenal primarily comprises of B cells and T cells. B cells recognize full and 
unique structural patterns found on pathogens with their B cell receptors 
(BCRs) whilst T cells recognize antigenic peptides, processed from 
pathogenic proteins intra-cellularly and presented by Major Histocompatibility 
Complexes (MHCs) on infected cell surfaces, with their T cell receptors 
(TCRs). In this way, both the pathogen and infected cells can be cleared by the 
immune system. As such, monoclonal antibodies, soluble forms of BCRs, 
have been developed as a therapeutic tool against various diseases with much 
success. However, a significant research gap exists for TCR therapeutics due 
to the many challenges faced in developing soluble and stable TCRs.  
 
1.1 Adaptive immune system 
 
All jawed vertebrates possess the adaptive immune system, which is crucial to 
protecting us against attacks by microbes and pathogens should our innate 
immune system fail to do so 1. More importantly, the adaptive immunity is 
coined as such due to the fact that it can adapt and confer long-term immunity 
by allowing for a memory response against recurrent infection. The adaptive 
immune system comprises mainly of two arms: B cells, which partake in the 
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humoural immune response, and T cells, which are responsible for cell-
mediated immune responses. 
 
T cells originate from Hematopoietic Stem Cells (HSCs) in the bone marrow 
and undergo development in the thymus where they undergo a selection 
process before entering into the periphery as naïve T cells 2. These T cells 
express a unique TCR each and are responsible for recognizing antigenic 
peptides presented by MHCs found on infected cells 3,4. Naïve T cells then 
patrol the periphery and lymph nodes searching for antigen. Dendritic cells 
(DCs), also known as professional antigen presenting cells, pick up pathogenic 
antigens and migrate to lymph nodes. T cells with TCRs specific for these 
antigens then contact and bind to the DCs presenting these antigens at the 
lymph nodes. These T cells are then activated, secreting cytokines such as 
Interleukin-2 (IL-2) and Interferon-γ (IFN-γ). They then dissociate from the 
DCs, proliferate rapidly and migrate to sites of infection 5. There are different 
subsets of T cells and their effector functions are different upon activation. 
CD8+ T cells, also known as cytotoxic T cells, recognize antigenic peptides of 
8-9 amino acid residues, either cytosolic or nuclear in origin, presented by 
class I MHC molecules 6. They kill off infected cells directly via cell-mediated 
cytotoxicity. CD4+ T cells, or T helper cells (Th), recognize exogenously 
derived antigens presented by class II MHC molecules 6. There are several 
different subsets of CD4+ T cells as well. Th1 cells mediate responses against 
intracellular pathogens, secreting IFN-γ to activate macrophages and IL-2 for 
CD8+ memory formation 7. Th2 cells secrete a milleu of cytokines such as IL-
4, IL-5 and IL-9, effecting class switching in B cells, recruiting eosinophils 
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and activating mast cells in response to extracellular parasite invasions 7. Th17 
cells secrete cytokines such as IL-17 and IL-22 as an immune response against 
bacteria and fungi 8. Once the infection is cleared, most effector CD8+ T cells 
will disappear with a small percentage becoming memory T cells, rapidly 
activating and proliferating in response to a recurrent infection. T regulatory 
(Treg) cells are also present at the end of an infection, secreting 
immunosuppressive cytokines such as IL-10 and TGF-β to prevent 
autoimmunity 9. 
 
On the other hand, B cells undergo development and selection in the bone 
marrow before entering the periphery. These naïve B cells express a unique 
BCR each and recognize structural patterns on full and intact antigens 
presented on cell surfaces or in soluble forms. Once bound to foreign antigens, 
B cells ingest the antigen and digest it, subsequently expressing the fragments 
on its class II MHC molecules. Activated CD4+ T cells that recognize the 
same antigenic peptides presented by the B cells can then contact these B cells 
and help them to proliferate and differentiate into plasma cells. Plasma cells 
then secrete antibodies which can bind to the pathogenic antigens with high 
affinity. Once bound, these secreted antibodies then carry out their effects via 
several mechanisms. First, by binding to the antigens expressed on pathogens 
or their toxic products, antibodies prevent their access, and thus harmful 
effects, to the host’s cells. Second, phagocytes such as macrophages and 
neutrophils recognize the antibody coated pathogens or toxins and ingest them 
in a process known as opsonization. Last, antibodies serve as receptors for 
complement proteins to be activated. The complement system, with several 
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different proteins such as c1q and c1s, can form an attacking complex to kill 
extracellular pathogens.  
 
There are five classes, commonly known as isotypes, of antibodies. IgM and 
IgD are isotypes of BCRs found on mature naïve B cells. IgE antibodies target 
allergens and parasitic worms including helminthes, and activate mast cells 
and basophils. IgA targets pathogens found in the mucosal areas such as the 
gut and respiratory tract whilst IgG is the major isotype that targets against 
invading pathogens.   
 
Other than targeting pathogens, the adaptive immunity also plays a part in 
combating cancer. First, it combats cancer indirectly by killing viruses which 
can cause cancer. Examples include the Epstein Barr virus, which is 
responsible for Burkitt’s and Hodgkin’s lymphoma 10, and the Human 
Papillomavirus, which is responsible for cervical cancer 11. Second, it can also 
eliminate cancer cells directly by specifically identifying the tumour antigens 
present on tumours and then killing them.  
 
With such a huge arsenal of weapons, both B and T cells play a huge role in 
protecting our body against invading pathogens and malignancies. Several 
studies have since been done to try and utilize them and their effector 





1.2 BCR recognition and diversity 
 
B cells are able to target antigens found on the pathogens themselves or 
expressed on the surface of infected cells. Each B cell contains a unique BCR 
and allows them to contact these antigens. In order to combat the huge 
repertoire of possible foreign antigens, a large diversity in the BCRs expressed 
by B cells is required.  
 
The BCR, also known as an immunoglobulin (Ig), is made up of two heavy 
chains and two light chains. Each chain contains a variable and a constant 
region, with the variable regions responsible for antigen recognition. Within 
the variable regions of each heavy and light chain are three hypervariable 
regions i.e. regions that are highly diverse between each BCR. They are also 
known as Complementary Determining Regions (CDRs) as they are the parts 
that contact the antigen the most. There are three CDRs in each heavy and 
light chain and they are responsible for the binding of antigens and thus, have 
huge variabilities. With the presence of two heavy and light chains, each 
antibody has two identical antigen binding sites. Thus, each BCR can 
theoretically bind to two target antigens. The large diversity in the binding 
regions of the BCR is generated primarily by the recombination of genes 
encoding for the variable regions (Fig. 1). For the light chain, Variable (V) 
gene segments and Joining (J) gene segments are recombined to produce the 
variable region of a light chain. A total of two gene loci, κ and λ, encodes the 
light chain of the BCR. Thus, each light chain could either be of the κ or λ 
subtype. On the other hand, the variable regions of the heavy chain are 
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encoded by the recombination of the V, J and Diversity (D) gene segments. 
Pairing of the recombined heavy and light chain for each BCR molecule adds 
another level of diversity to their variable regions. In addition, more diversity 
is generated as nucleotides are gained or lost randomly during joining of the 
various gene segments. This is known as junctional diversification and 
together with the recombination of the various gene segments and pairing of 
the heavy and light chains, a large and diverse repertoire of BCRs is 
generated. With such a huge diversity, it is not surprising that there will be 
BCRs which can recognize self-antigens. If these BCRs were allowed to enter 
the periphery, they will generate an autoimmune reaction. To prevent this 
from happening, a selection process occurs in the bone marrow to ensure the 
BCRs assembled are not reactive to self-antigens, before the B cells are 
released into the periphery. If the B cells are reacting with self-antigens, they 
are given a second chance to modify their BCRs by going for a second round 
of recombination in a process known as receptor editing. B cells that still 
produce self-reactive BCRs are then deleted.  
 
In addition to diversity generated during B cell development, more diversity in 
the BCR can be created upon contact with antigens and with T helper cell 
stimulation, in a process known as affinity maturation. As B cells get 
stimulated, they divide and accumulate point mutations in their BCRs’ 
variable regions. These mutations occur approximately once every cell cycle, 
a rate many times faster than spontaneous mutation in other genes. Thus, this 
process is referred to as somatic hypermutation (SHM). SHM generates a 
small number of BCRs with increased affinities for the target antigen but 
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many more has either little or no effect on their binding affinities to the 
antigen. B cells expressing BCRs with higher binding affinities are then 
preferentially stimulated to survive and proliferate. After several rounds of 
proliferation and SHM, a pool of B cells expressing BCRs with much higher 
binding affinities to the antigen is generated. In this way, affinity maturation is 
achieved with surviving B cells expressing BCRs which can bind to the target 
antigens with high specificity. In the event of a recurrent infection, the 
antibodies produced upon recall would also be of a high binding affinity, 
shortening the time to resolve the insult.     
 
Figure 1. Recombination Mechanisms of T and B cell receptors. Diversity of the T cell 
receptor (TCR) can be achieved from the (1) V(J) recombination of the α chain and V(D)J 
recombination of the β chain, (2) nucleotides added or deleted in the joined segments and (3) 
pairing of the re-arranged α and β chains. Similarly, diversity of the B cell receptor (BCR) can 
be achieved from the (1) V(J) recombination of the light chain and V(D)J recombination of 
the heavy chain, (2) nucleotides added or deleted in the joined segments and (3) pairing of the 
re-arranged heavy chain with either the κ or the λ isotype of the light chain. Further diversity 
is created when the re-arranged BCR undergoes somatic hypermutation upon contact with 




1.3 BCR therapeutics: monoclonal Antibodies (mAbs) 
 
In terms of mAbs, much work has been done to utilize them against several 
diseases since Milstein and Kohler first generated them 15. In the beginning, 
unmodified mouse mAbs have limited therapeutic efficacy due to them being 
immunogenic to humans, having short survival times in vivo as well as their 
inability to kill target cells efficiently with the human complement counterpart 
16. With that, human and humanized antibodies were developed to better the 
therapeutic effects of mouse mAbs 17,18. With their high affinities and 
specificities, they were soon used with large success as therapeutics against 
cancer and other diseases 19. To enhance the killing of their targets, mAbs are 
also tagged with radionuclides, drugs or toxins 20 and several have been 
approved by FDA 21. A much larger number of mAbs are in clinical trial 
phase, further cementing their role in the future of immunotherapy 22.   
 
Despite so, mAbs are not without their own limitations. First, due to their 
large size, approximately 150kDa, mAbs exhibit slow extravasation from 
circulation 23. Second, the Fc region of mAbs can interact with several 
different receptors found on various cell types. This increases their retention 
time in circulation in addition to their large size. An example of receptors 
binding to antibodies is the neonatal Fc receptor (FcRn). It is highly expressed 
on the surface of cells such as vascular endothelium cells and monocytes, as 
well as in barrier sites such as the blood-brain barrier and the glomerular filter 
in the kidneys 24. Upon phagocytosis after binding to FcRn, mAbs can still 
retain their binding even at low pH in endosomes. This prevents them from 
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heading to the lysosomes for degradation and they are then shuttled to and 
released at the neutral pH of cell surfaces, prolonging their retention time in 
circulation 25. Third, the high binding affinities of the mAbs can be a double-
edged sword. Other than conferring upon them high specificity, too strong a 
binding can be detrimental too. A good example is seen in tumour targeting 
where high affinity antibodies have had suboptimal therapeutic effects 26. This 
is due to a phenomenon known as the binding site barrier effect, where 
penetration into the tumour is drastically reduced as mAbs bind too strongly to 
their targets upon first encounter 27. In contrast, molecules with moderate 
binding affinities can penetrate deeper after they reach equilibrium between 
binding to and releasing from their targets. Last, mAbs target full and intact 
antigens, which account for only a fraction of the repertoire of antigens in our 
bodies. On the other hand, MHC molecules present peptide antigens from 
pathogens 28, self derived peptides 29 and tumour-associated peptides 30. These 
peptide antigens represent a larger and alternative pool of antigens, serving as 
distinguishing factors between normal and transformed or infected cells. T 
cells, through their TCRs, can target these antigens which are distinct from the 
pool sampled by antibodies. With this in mind, much work has been done to 
marry the two molecules, giving rise to TCR-like antibodies: mAbs that can 
target peptide MHC molecules. These antibodies have shown high specificity 
against MHC molecules presenting tumour-associated or viral-derived 
peptides and have been considered as alternative therapeutics against cancer 
and infectious diseases 31. However, being an antibody, they still face similar 
disadvantages as discussed above. 
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Efforts to counter some of the limitations of mAbs as mentioned above gave 
rise to the design and production of different forms of antibodies (Fig. 2). One 
of them would be the single chain antibody (scFv). Their small size would for 
one facilitate tissue penetration. They can be created from relatively easy 
procedures such as E. coli expression and selected via phage display for 
improved binding affinities 32. In addition, they do not contain the Fc region, 
which is responsible for prolonged retention in circulation as mentioned 
above. scFvs have been shown to be able to counter pathogens such as 
Hepatitis C virus 33 and Human Immunodeficiency Virus (HIV) 34. 
Pexelizumab, a recombinant humanized scFv against C5 of the complement 
system, has also shown success in preventing complement-mediated damage 
to tissue during heart surgery 35,  scFvs have also been used in cancer therapy 
after being fused with effector molecules such as radionuclides to generate 
anti-cancer therapeutics 36. Other than as therapeutic agents, scFvs can be 
tagged to a radioactive label and be used as a tumor imaging agent 37. They are 
chosen for their specificity against tumour antigens as well as their small size, 
conferring upon them the ability to penetrate into solid tumours and rapid 
clearance from the blood. Several other applications of scFvs are further 
reviewed by Blazek and Celer 38. 
 
Another type of antibody developed is the bispecific antibody (Fig. 2). As 
mentioned earlier, each antibody possesses two antigen binding “arms” and is 
thus able to bind theoretically to two identical antigens. Bispecific antibodies 
are designed such that each arm can bind to a different antigen. 
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Figure 2. Different types of monoclonal antibodies. The antibody molecule consists of a 
pair of identical heavy chains and a pair of identical light chains, joined by disulphide bridges. 
Several other forms exist and they include the Fab molecule, which comprises of the light 
chain and the variable region of the heavy chain, and a smaller version of the Fab region, the 
scFv (Single chain Fv), where the variable regions of the light and heavy chains are joined 
together. In addition, the valency of an antibody can also be increased as seen in bi-specific 
antibodies where a heavy-light chain pair specific for an antigen (blue) is bound to another 
pair with a different specificity (orange), conferring dual specificity to the antibody. An 
example would be Bi-specific T cell Engagers (BiTEs) where the antibody is specific for both 
the antigen of interest and the CD3 molecule found on T cells. Smaller versions such as Fab’2, 
tandem ScFv, diabodies and minibodies are also functional designs. 
 
First generation bispecific antibodies were generated either via chemical 
cross-linking of different antibodies or from hybridomas of two different 
antibodies 39. Both methods proved difficult to produce antibodies in large 
homogenous batches and the resulting antibodies are highly immunogenic, 
leading to reduced efficacy 40. In addition, these antibodies do not show much 
therapeutic effects 41. The next generation of bispecific antibodies looks to 
reduce their sizes with much being done on improving the scFv design. One 
design is the tandem scFv (TaFv) where two scFv fragments of different 
specificities are joined by a peptide linker (Fig. 2). This form of antibody has 
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shown some success as a therapeutic molecule. An example can be seen in 
rM28, an antibody specific for CD28, a T cell co-stimulatory molecule, and 
NG2, a proteoglycan associated with melanoma. This antibody has been 
shown to induce T cell activation and kill tumour cells in both in vitro and in 
vivo settings 42. Another design involves the reduction of the length of the 
peptide linker in TaFv, forcing the two Fv domains into a more compact 
structure known as a diabody (Db) 43. There are also successful examples of 
this version of antibody in targeting cancer, albeit only in pre-clinical trials. 
An example is treatment with peripheral blood lymphocytes and a diabody 
specific against both PSMA (Prostate Specific Membrane Antigen) and CD3 
is effective on mice with prostate cancer induced tumours 44.  
 
One of the more successful TaFv in clinical trials would have to be BiTE  
(Bispecific T cell Engagers) antibodies (Fig. 2). They are generated by fusing 
an anti-CD3 scFv to another scFv recognizing a tumour associated antigen of 
interest. The rationale behind this design was that T cells have been found to 
be tightly linked to the overall survival of patients in cancer 45,46, treating even 
late-stage solid tumours such as melanomas 47. Thus, activating T cells to kill 
tumour cells would be an effective strategy. BiTE antibodies have been 
relatively successful in clinical trials due to a couple of reasons. First, it does 
not require any pre or co-stimulation of T cells as it is able to activate T cells 
with its anti-CD3 component. Second, it neither requires specific T-cell clones 
nor normal levels of antigen presentation for its effect to occur. This is due to 
the fact that the CD3 molecules for all T cells are the same and being an 
antibody, BiTE antibodies can bind to their antigens with high affinities. 
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Third, very low concentrations of these antibodies are required to achieve anti-
tumour effects. These properties of BiTE antibodies make them extremely 
attractive as cancer therapeutics. An example of a successful BiTE antibody is 
Blinatumomab. It comprises of an anti-CD3 scFv fused to an anti-CD19 scFv. 
It was reported that non-Hodgkin lymphoma patients treated with cumulative 
doses of several milligrams of Blinatumomab saw tumour regression as 
compared to conventional mAb treatments which would require grams per 
treatment 48. With such a high therapeutic efficacy, BiTE antibodies targeting 
other cancers as well as new approaches to generate them rapidly are being 
developed 40. 
 
Despite the success seen in targeting cancer, there are certain drawbacks for 
BiTE antibodies as well. For instance, the activation of polyclonal T cells may 
lead to non-specific killing of the surrounding healthy cells via the 
“bystander” effect. In addition, due to its small size (~60kDa), BiTE 
antibodies have a short serum half-life and thus, infusion of the drug would 
have to be carried out frequently over a treatment cycle. Further developments 









1.4 TCR recognition and diversity 
 
T cells, together with their TCRs, are also capable of resolving several acute 
infections 49,50 and targeting cell malignancies 51,52. In contrast to antibodies, T 
cells target peptide antigens presented by MHCs. Several types of peptide 
antigens can be presented and they include epitopes from viruses such as 
Influenza, bacteria such as Listeria monocytogens, parasites such as 
Toxoplasma gondii, as well as tumour associated antigens. These peptide 
antigens constitute an alternative pool of antigens not recognized by 
antibodies and the number of potential foreign peptides in our body has been 
estimated to be larger than 1015 53. Thus, T cells serve as an important tool to 
combat diseases caused by intracellular pathogens and cell malignancies. 
 
T cells recognize peptide loaded MHCs (pMHCs) via their TCRs. The identity 
of each T cell is characterized by the unique TCR that it expresses. The TCR 
is a membrane-associated receptor that comprises of two chains, an α chain 
and a β chain. TCRs are highly variable and rightly so as they need to 
recognize a large pool of peptide antigens. This variability is due to the 
random re-arrangement of several variable (V) genes and junction (J) genes at 
the α chain locus, and V, diversity (D) and J genes at the β chain locus (Fig. 
1). In addition, junctional diversity is created by the random addition or 
deletion of nucleotides during the recombination process at junctions of exons, 
adding another level of variability to the TCR. Similarly to the antibodies, 
there are three hypervariable regions, also known as CDRs, found on the α and 
β chain. These CDRs are responsible for contacting the antigenic peptide, as 
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well as the MHC molecule presenting it. Upon successful generation of the 
heterodimeric TCR, T cells undergo selection in the thymus. T cells 
expressing TCRs that bind too weakly or too strongly to self-MHC are 
negatively selected and those that bind with intermediate strength to MHC 
presenting self-peptides then become either CD4+ or CD8+ T cells in a positive 
selection process. This selection process ensures T cells that enter the 
periphery can recognize foreign peptides presented by self-MHC but at the 
same time, they are not binding strong enough to MHC presenting self-
peptides to cause autoimmunity. An estimated repertoire of 107-108 of T cells 
expressing unique TCRs enter the periphery at the end of the selection process 
54.  
 
Much work has been channeled into identifying T cell epitopes. It began with 
Altman and colleagues producing fluorescently labeled multimeric pMHCs 
and using them to stain antigen specific T cells 55. In a typical way of T cell 
epitope identification, MHCs presenting a library of peptides can be used to 
stain T cells from patients with the disease of interest. Disease specific T cell 
epitopes can then be picked simply from those that stained the T cells isolated 
from the patients. However, this technology is limited to the analysis of a 
small set of antigens due to the laborious process of producing each pMHC 
complex i.e. refolding each pMHC complex with the peptide of interest. The 
group of Ton Schumacher then developed a MHC peptide exchange 
technology which allows the creation of a large number of unique pMHC 
molecules in a fraction of the time previously required 56. Briefly, it entails 
expressing the MHC molecule with a UV-cleavable conditional ligand and 
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then exchanging it with any peptide of interest after UV irradiation. This has 
since allowed for high throughput screening of antigen specific T cell 
responses and enabled the screening of peptide libraries to identify novel 
disease-specific epitopes. With that, this method has spawned further 
developments and studies identifying new epitopes from several pathogens 
such as Chlamydia trachomatis 57 and Toxoplasma gondii 58. On a larger scale, 
databases and peptide libraries have also been developed to facilitate the 
identification of novel antigenic epitopes of various diseases. The Immune 
Epitope Database and Analysis Resource (IEDB) is a database online with 
data pertaining to antibody and T cell epitopes for humans and several 
organism models relating to all infectious disease (www.iedb.org). The group 
of Grotenbreg has also recently created a library of UV-cleavable ligands 
expressed by MHC variants specifically targeting the South East Asian 
population 59. With this library, they managed to characterize seven novel T-
cell epitopes from Severe acute respiratory syndrome coronavirus, Hepatitis B 
virus and Dengue virus. Newell et. al. have also developed a new technique 
combining combinatorial pMHC tetramer staining and mass cytometry 
analysis to identify epitopes which are recognized by T cells from different 
individuals 60. As such, the epitope discovery tools and databases are 
established and further developing, making the identification of disease-
specific T cell clones easier.  
 
In addition, after the identification of disease specific T cell clones, it would 
be useful to test if these clones are indeed protective in an in vivo setting. 
Mouse models expressing the TCR of interest can be generated and infected 
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with the disease to ascertain its therapeutic efficacy. Current TCR transgenic 
mouse models are not only technically challenging to generate, they are also 
generated from T-cell clones or hybridomas selected for response to antigens 
in vitro and survival. These criteria skews the TCRs selected and may not 
accurately reflect the affinities and activation requirements of T cells triggered 
during an infection. Recently, Kirak et. al. reported a method to generate 
transnuclear mice monoclonal for TCRs via somatic cell nuclear transfer 61. Of 
particular interest is the relative ease and speed of generating these 
transnuclear mice and most importantly, these mice are monoclonal for TCRs 
isolated at the peak of resolving a T. gondii infection, making them an 
accurate reflection of an actual response. With the technology to generate 
these mice, one will be able to investigate the protective potential of the 
isolated T cell clones in an in vivo model by infecting the transnuclear mice 
with the pathogen.    
 
With its ability to recognize a large array of intracellular pathogenic and 
cancer antigens, coupled with the availability of several tools and databases to 
identify T cell clones specific for several diseases, and eventually being able 
to prove their protective capabilities in an in vivo setting, a great amount of 
potential exists for TCR therapeutics. To date, two types of TCR therapeutics 
have been developed, namely adoptive T cell transfer and soluble TCRs. Both 
types of therapeutics have had successes in treating diseases but possess 




1.5 TCR therapeutics: Adoptive T cell transfer  
 
As mentioned above, T cell therapeutics can be envisioned to encompass two 
arms. One would be using antigen specific T cells in adoptive T cell transfer 
whilst the other would be utilizing soluble T cell receptors as therapeutic tools. 
Adoptive T cell transfer has seen much success in the treatment of cancer and 
can be broadly classified into two categories. One, using Tumour Infiltrating T 
Lymphocytes (TIL) and the other, using TCR or Chimeric Antigen Receptor 
(CAR) transduced T cells. 
 
TILs are lymphocytes that have migrated from the peripheral bloodstream and 
into the tumour. Thus, they are specific for tumour-associated antigens and 
can be selected from tissue surrounding the tumour. These T cells are then 
cultured to a large enough number, over a few weeks, before infusing them 
back into the patient. This is usually done together with IL-2, a T-cell growth 
factor, and also radiation or drug therapy to deplete endogenous immune cells 
so that they do not suppress the transfused T cells. TIL has seen much success 
specifically targeting melanomas 62,63 and less so against other cancers such as 
leukemia as it would be more difficult to obtain tumour-specific T cells from 
blood or organs. 
 
However, this can be circumvented with the use of TCR or Chimeric Antigen 
Receptor (CAR) transduced T cells. By identifying antigen specific T cell 
clones against cancer or viral epitopes, the gene sequences encoding the TCR 
of interest can be cloned into a vector and retro-virally transduced into the 
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host’s T cells. It has been shown that increasing the binding affinity of the 
transduced TCR to its specific antigen can potentially increase the protective 
capacity of T cells used for adoptive transfer 64. Thus, this method also allows 
one to modify the TCR, such as enhancing its binding affinity, before 
transduction into T cells.  
 
Unlike TCRs, CAR represents a different class of receptor. It contains 
antibody-based recognition domains linked to signaling sequences to activate 
the transduced T cell 65. It can also be modified to include molecules involved 
in co-stimulation 66, as well as molecules to proliferate 67 and persist in the 
host 68. The main advantage of CARs is that it does not need to be immune-
matched to the patient receiving the therapy, due to the fact that CAR binds to 
antigens like that of an antibody, disregarding the need for MHC class 
restriction, unlike TCRs. Adoptive T cell transfer with CARs have shown 
several successes in combating cancer 69. Together, adoptive T cell transfer 
has shown its effectiveness in the regression of tumours in breast, prostate, 
ovarian and colorectal cancers 70. Other than cancer, adoptive T cell transfer 
can also confer protective immunity against several viruses such as 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in both murine models 
and human patients 71. This further broadens the scope of diseases that this 
therapy can effect upon. 
 
However, there are limitations to adoptive T cell transfer as a therapy. T cell 
receptors have been shown to be cross-reactive to other antigens other than 
that which they were selected against 72. This could potentially be dangerous 
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as the infused T cells may attack other normal tissue. Researchers at the US 
National Cancer Institute were using MAGE-A3 specific TCR-engineered T 
cells to treat cancer patients in a clinical trial. Two out of nine patients slipped 
into a coma and died as these transferred T cells also targeted another member 
of the MAGE-A family expressed at low levels in the brain 73. In another 
example, another MAGE-A3-specific TCR recognized a similar protein, Titin, 
found in the heart, leading to death of the patients receiving the T cells 
transfusion 74. Thus, care has to be taken to ensure that the engineered TCRs 
do not cross-react strongly with other self-peptides. Another limitation would 
be the possibility of a “cytokine storm” being generated as the transfused T 
cells attack and kill their target cells, at a rate much higher than which the host 
can handle, without suppression. A large milieu of cytokines is generated in 
the process and this can damage healthy cells, even causing death to the 
patient receiving the therapy 75. 
 
In addition, it is important to choose the appropriate subsets of T cells to 
transfer given that there are different types of T cell subsets such as naïve, 
effector and memory T cells. For example, Hinrichs et. al. reported that 
effector cells derived from naïve T cells have superior antitumour immunity as 
compared to central memory derived ones in mice 76. On the other hand, 
Berger et. al. proposed that effector CD8+ T cells derived from central 
memory T cells persisted longer in macaques 77. Thus, time and effort would 
need to be spent on the careful selection of cells for transfer to maximize the 
full therapeutic potential of this approach.      
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1.6 TCR therapeutics: Soluble TCRs 
 
Another arm of T cell therapeutics would be soluble TCRs. They can be 
considered as an alternative platform to mAbs as they target a different set of 
antigens. In addition, being a targeting “device”, soluble TCRs also have the 
potential to be tagged to effector molecules. This allows the targeted delivery 
of various effector molecules such as drugs and toxins to the sites of interest, 
localizing the toxic effects the effector molecules bring. Potentially, soluble 
TCRs usage can be applied in several areas such as autoimmunity, cancer and 
infectious diseases (Fig. 3). 
 
In autoimmunity, autoimmune T cells can recognize normal host cells 
presenting self-peptides as foreign and start to attack them. Soluble TCRs can 
be employed in this case to compete with endogenous T cells, preventing their 
attack on normal cells (Fig. 3). Despite the potential therapeutic effects of 
soluble TCRs in combating autoimmunity, very few autoimmune antigens 
have been identified and these antigenic epitopes are not fixed i.e. ‘epitope 
spreading’ can occur in many autoimmune diseases 78. However, as more 
work is carried out to identify autoimmune antigens, causative agents for 
several diseases such as Type I diabetes 79 and autoimmune hepatitis have 
been identified 80. Type I diabetes is an autoimmune disease where the insulin-
producing beta cells are being destroyed by the host’s immune cells. 
Immunosuppressive strategies such as the blocking of autoreactive T cells 
with mAbs have proven successful 81. Thus, soluble TCRs can also potentially 
achieve the same effect by outcompeting the autoreactive T cells, preventing 
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them from binding to these beta cells and killing them. In addition, therapeutic 
responses to Rheumatoid Arthritis, another autoimmune disease, have been 
found to be most optimal when CD4+ T cells were blocked by antibodies 
instead of being depleted, suggesting that modulation of the CD4+ T cells, and 
not their depletion, is key to treating the disease 82. If so, soluble TCRs can 
similarly be envisioned to compete with the endogenous CD4+ T cells for 
binding to their cognate antigens, preventing their activation. The dosage of 
soluble TCRs administered can also be adjusted to achieve an optimal level of 
CD4+ T cell response for maximum therapeutic effects. Next, changes in the 
cytokine environment can also affect disease progression. In the case of 
diabetes, a shift in polarization of T helper cells from Th1 to Th2 can help to 
prevent its advent 83. Thus, Th2 promoting cytokines such as IL-2 and IL-4 
would then be useful to promote the differentiation of Th2 cells. In addition, 
immune inhibitory molecules, such as IL-10 and IL-13, have a positive effect 
on Type I diabetes as well 84,85. However, systemic administration of these 
cytokines would lead to a decrease in the host immune response, increasing 
the host’s susceptibility to infections or cancer. Thus, by tagging them to 
soluble TCRs, these cytokines can be targeted to the site of interest, reducing 
their effects in systemic circulation. A good example could be seen in the 
treatment of Inflammatory Bowel Disease where localized administration of 
IL-10 have significantly higher therapeutic effects as compared to those 
administered via a systemic route 86. In another example, soluble TCRs can be 
used as a vaccine, priming TReg cells and preventing antigen-induced EAE 
(Experimental Autoimmune Encephalitis) in mice 87. Thus, it would seem that 
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soluble TCRs have great potential as therapeutics against several autoimmune 
diseases. 
 
In cancer, much work has also been carried out to identify TAAs (Tumour 
Associated Antigens) as they distinct cancer cells from normal ones. As such, 
several mAbs have been developed to target these antigens 88. 
 
Figure 3. Potential uses of soluble TCRs. Soluble TCRs can be envisioned to be effective as 
therapeutics in autoimmunity, cancer and infectious diseases. Self-proteins, tumour proteins 
and pathogenic proteins are degraded by proteasomes in cells and the various peptides are 
then loaded onto MHC class I and presented on cell surfaces. Soluble TCRs can bind to MHC 
class I presenting self-peptides and inhibit autoreactive T cells from binding and generating an 
autoimmune response. They can also be used to target cancer cells by tagging them with 
toxins or radionuclides. Neighboring cancer cells can also be killed this way. Last, effector 
molecule tagged soluble TCRs can also be used to activate effector cells in the vicinity of 
pathogen infected cells, leading to the killing of diseased cells.  
 
Many TAAs, such as the cancer testis antigen NY-ESO-1, can be recognized 
by both B cells and T cells 89. In addition, a larger pool of TAAs are expressed 
intra-cellularly and most, if not all, TAAs can be processed to become TAPAs 
(Tumour Associated Peptide Antigens) presented by MHC molecules on the 
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tumour cell surface 30,90. With such a huge milieu of antigens, soluble TCRs 
serve as an attractive therapeutic tool to potentially target cancer cells 
specifically (Fig. 3). However, there are potential limitations with the use of 
soluble TCRs as targeting devices. First, MHC molecules are highly 
polymorphic among individuals. Since TCRs are specific for both MHC class 
and peptide, it will be an extremely huge challenge to generate soluble TCRs 
that provides a complete coverage for all cancer patients. However, there are 
human class I MHC alleles that are rather common in different ethnic 
populations. For example, HLA-A*0201 is quite common among Caucasians 
whilst HLA-A*24 represents a fair share of MHC class present in the Asian 
population 59. Thus, targeting a few classes of MHC can still generate a huge 
coverage. For example, in the Caucasian population, targeting three different 
MHC Class I molecules would cover close to 85% of the population 91. This 
shows that soluble TCRs are still attractive as TAPAs targeting devices 
against cancer. Second, there are cases where tumour cells can down-regulate 
surface Class I MHC expression in a bid to escape the host’s immune system 
92. However, this is not universal and the presence of natural killer (NK) cells 
would ensure that at least a very low level of MHC expression is maintained 
on tumour cells. Thus, soluble TCRs can still remain an attractive tool for 
targeting cancer cells, albeit with their binding affinities enhanced. 
 
Since soluble TCRs can specifically target TAPAs i.e. they can act as a 
“warhead”, they can be conjugated to several effector molecules, or 
“payloads”, such as drugs, toxins, radionuclides or immuno-modulatory 
protein molecules to kill cancer cells specifically. In contrast to current 
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chemotherapies where patients suffer several side effects due to the non-
discriminate killing of cancer and healthy cells, this approach will allow for 
localized and specific killing of the tumour cells, reducing the amount of 
damage to normal cells. Successful examples include fusing soluble TCRs 
with exotoxin A protein to specifically kill p53 peptide antigen presenting 
cells 93 and coupling IL-2 to reduce lung metastases in a mouse tumour model 
94. By tapping onto work already done for antibody immuno-conjugates, 
several effector molecules such as IL-12 and TNFα can also be conjugated to 
soluble TCRs for killing tumour cells 95.      
          
As mentioned earlier, several T cell epitopes for various infectious diseases 
such as Influenza, Hepatitis B and Toxoplasmosis have been identified. Thus, 
soluble TCRs can also be envisioned to target cells infected by these 
pathogens (Fig. 3). In influenza, CD8+ T cells are crucial in clearing the 
influenza virus via perforin or Fas-dependent pathways 96. Thus, soluble TCRs 
specific for influenza epitopes can be conjugated with these molecules for 
specific killing of infected cells. In Toxoplasmosis, the disease caused by the 
parasite Toxoplasma gondii and estimated to infect 30%-65% of the world’s 
population 97, protective immunity against this parasite is dependent on 
cytotoxicty mediated by T cells and IFN-γ production 98,99. In addition, other 
than IFN-γ, CD40 has also been shown to play an instrumental role in clearing 
Toxoplasma infection 100. Thus, soluble TCRs targeting the various 
toxoplasma-specific antigens, and conjugated to either IFN-γ or CD40, can 
potentially be a powerful tool to kill Toxoplasma infected cells.  
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Currently, a research gap exists between using mAbs and using soluble TCRs 
as therapeutics, with much more work done on mAbs. One of the reasons is 
because the production of soluble TCRs has proven to be very challenging. 
TCRs are membrane bound molecules expressed on the surfaces of T cells. 
Thus, soluble forms of TCRs would not be as stable as membrane-bound ones. 
To that end, several refolding strategies have been employed to aid the 
refolding of soluble TCRs. TCRs are heterodimers consisting of an α and a β 
chain bound together non-covalently on the surfaces of T cells. The earliest 
strategy sought to refold TCRs as a single chain molecule by combining the 
variable regions of both the α and the β chains with a protein linker 101-103. To 
date, this technique is still being used and the TCRs generated has been 
proven to be refolded correctly and used for several studies 104,105. Other 
strategies include introducing jun/fos leucine zippers to the extracellular 
domains of the TCR chains to aid in their binding 106. Recently, Boulter et. al. 
introduced a non-native disulphide bridge in the constant regions of the α and 
β chains to aid in the refolding of soluble TCRs and this method produced 
functional and stable TCRs that are even amenable for protein crystallization 
107. The non-native disulphide bridge at the constant region is the only change 
in the TCR and thus, soluble TCRs produced by this method has minimal 
changes made to it.   
 
Although there are several ways to generate soluble TCRs, they may not be as 
stable as their native membrane-bound counterparts. If they were to be used as 
potential therapeutics, their stabilities would be important as it would directly 
impact on their abilities to reach the target site of interest, maintain structural 
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integrity and recognize their cognate epitopes. Recent studies have shown that 
by increasing the surface charges of proteins, a process termed 
“supercharging”, the stabilities of several different types of proteins such as 
Green Fluorescence Protein (GFP) and antibodies have been increased 108,109. 
However, it remains to be explored if this method can increase the stabilities 
of soluble heterodimeric TCRs as well. 
 
1.7 Supercharging to improve stabilities of soluble TCRs 
 
One huge challenge faced in utilizing soluble proteins as therapeutics would 
be problems pertaining to their stabilities and aggregation. Most protein drug 
candidates undergoing development are discarded, usually due to either 
solubility or aggregation problems 110. The problems caused by aggregation of 
a protein-based drug are several folds. It may not only reduce their 
bioavailability and therapeutic activities but can also increase chances of 
immunogenic reactions against them 111. An example of aggregated protein 
causing diseases would be the aggregation of amyloid β-peptide forming 
plaques in Alzheimer’s disease 112. In addition, aggregation will also 
compromise the yield of the proteins. This will inevitably translate to high 
costs as large amounts of time and input material will be needed to produce 
only a small amount of refolded protein. Thus, it will be beneficial to look into 
how to improve the stability of a protein-based therapeutic. Protein stability 
can be affected by the surrounding physical conditions such as temperature 
and pH 113. They can also be affected by physical properties, such as charges, 
of the protein itself. 
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The solubility of proteins in non-organic solvents, water for example, can be 
envisioned by the amount of ionic interactions the protein makes with the 
solvent. Studies have shown that a correlation exists between the net charge of 
a protein and its stability with proteins being least stable at their isoelectric 
point i.e. they have zero net charges 114. Differences in net charges between 
various peptide variants have also shown correlation with their propensity to 
form aggregates 115. There exists a group of proteins encoded by eukaryotic 
genomes which are intrinsically disordered by nature 116 Although this group 
of proteins have large regions of disordered structure, they do not aggregate 
and are not degraded by the cell rapidly. Instead, they have specific functions 
connected to cell cycle control, transcriptional and translational control 117. 
Interestingly, high net charges seem to be a factor in reducing the propensity 
of these proteins to aggregate 118,119. Moreover, there are evidence of proteins, 
carbonic anhydrase for example, which can retain their functional activities 
even after having their net charge drastically modified 120. 
 
These findings spurred the group of David R. Liu to investigate if increasing 
the net charges of proteins, a process they termed “supercharging”, could 
increase the stability of proteins 109. In this study, they used an improved 
version of GFP, which refolds with a better yield, as a starting construct and 
mutated amino acid residues which are highly exposed to solvent to either 
positively or negatively charged ones. With that they created GFP with net 
charges +48, +36, -30 and -25, much higher than -7, the net charge of the 
original construct. Characterizing these “supercharged” GFP revealed that 
they have similar secondary structures and produced similar levels of 
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fluorescence as compared to the original construct. Importantly, GFP (+36) 
and GFP (-30) were significantly much more resistant to aggregation, as 
compared to the original construct, under chemical or thermal denaturation. In 
addition, they “supercharged” Glutathione-S-transferase, a dimeric enzyme, 
and streptavidin, a tetrameric protein. In both cases, the supercharged versions 
were able to resist aggregation under denaturing conditions and were able to 
restore partial functions after reverting back to normal conditions 109.      
 
With this pioneering work, the group of David Liu went on to further 
characterize the properties of “supercharged” GFP. McNaughton et. al. 
reported that by using GFP (+36) as a delivery vehicle, they were able to 
penetrate the cell membranes of  a variety of cell lines, delivering siRNA into 
these cells 121. Cronican et. al. then went on to investigate if supercharged 
GFP could deliver protein molecules into cells better than protein transduction 
domains currently used 122. In this study, they first fused GFP (+36) with a 
fluorescent protein and delivered it successfully into various cell lines. They 
then fused GFP (+36) with an enzyme, Cre recombinase, and delivered it into 
various cell lines too. Importantly, the function of the Cre recombinase was 
preserved even after it was delivered into the cell. Thus, other than being less 
prone to aggregation, “supercharged” proteins can also act as a delivery 
vehicle, increasing the amount of protein delivered into cells as compared to 
current protein transduction domains such as oligoarginine 123. Finally, Miklos 
et. al. then applied this strategy to scFv antibody and not only enhanced its 
resistance to thermal inactivation, the affinity of the antibody was also 
improved in the process 108.  
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Thus, it would seem that “supercharging” is able to impart additional 
resilience to proteins, improve their uptake by cells and in certain cases, 
improve the binding affinities of proteins to their targets. With that, it would 
seem promising to test this strategy on soluble TCRs, where no data has been 





















Chapter 2: Production and characterization of 3 TCR clones with 




T cells represent the cell-mediated immunity arm of the adaptive immune 
system. They are not only important in resolving acute infections by 
pathogens, they are capable of becoming memory such that an immune 
response can be mounted promptly in the event of a recurrent infection. T cells 
have since been shown to play important roles in combating diseases from 
viruses such as influenza 124 and parasites such as Plasmodium 125 and 
Toxoplasma 126.  
 
As viruses and parasites infect cells, they hijack the host cell machinery to 
produce pathogenic proteins. In response, the infected cell degrades these 
foreign proteins with proteasomes and loads them onto Class I MHC 
molecules with the help of the TAP (Transporter associated with Antigen 
Processing) protein. These peptide loaded MHCs then translocate to the cell 
surface, acting as markers of infection for T cells 127. Thus, TCRs recognition 
of MHC molecules presenting pathogenic peptides would be crucial in 
identifying and killing infected cells. With the huge number of peptides that 
can be presented by MHC molecules, a large and diverse repertoire of TCRs 
would be needed to recognize them and this is achieved mainly from the 
recombination of the TCR α and β gene loci.  
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Despite the diverse repertoire of T cells, biasness in the selection of TCRs 
against several viruses have been observed 54,128. Some examples include 
identical TCR clones isolated from different individuals against the Epstein 
Barr Virus (EBV) 129 and highly homologous TCR clones against Influenza 
130. In addition, Kjer-Nielsen et. al. have observed that how TCR binds to its 
ligand affects the intracellular signaling of the T cell, thus proposing TCR 
biasness or immunodominance may be linked to structural properties affecting 
the specificity of the TCR 131. Understanding how TCRs bind to their cognate 
pMHCs will then be crucial to improve the immune response against various 
diseases and immunotherapeutic approaches against them.   
 
The parasite Toxoplasma gondii causes a ubiquitous infection estimated to 
infect approximately 30%-65% of the world’s population 97. There are several 
life stages of the parasite (Fig 4). In its proliferative stage, also known as 
tachyzoite, the parasite replicates exponentially via asexual division, 
disseminating clonally through the host. In its latent stage, known as 
bradyzoite, the tachyzoites are enclosed in a membrane-bound compartment 
called the parasitophorous vacuole and exists as cysts in tissues of infected 
hosts 132. These cysts can be found in the brain, retina and other organs of 
infected hosts. They are infectious and can act as a medium to spread to a new 
host. The sexual stage of the parasite, or oocyst, only occurs in the guts of cat 
where bradyzoites are induced to differentiate into macrogametes and 
flagellated microgametes. These then fuse to form oocysts which are highly 
stable and infectious. Humans can be infected from various routes such as 
eating or handling raw or undercooked meat containing the parasite. Another 
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route of infection can result from direct contact with cats or from food/water 
sources contaminated with faeces of infected cats.
 
Figure 4. Various life stages of the parasite Toxoplasma gondii. Toxoplasma exists as 
oocysts, the sexual stage of the parasite, in the guts of cats. They can then infect humans or 
animals that come into close contact with these infected cats. The oocysts then develop into 
the latent form (bradyzoites) in animals. Healthy humans who ingest these infected animals 
will then be infected by the parasite. Toxoplasma exists as bradyzoites in humans but 
develops into its proliferative stage (tachyzoites) when the host becomes 
immunocompromised. Tachyzoites in pregnant mothers can also infect their unborn child, 
leading to fetal complications, including death. (Illustration adapted from Sullivan Jr and 
Jeffers 132) 
 
Other than infecting adults, toxoplasma can infect infants as well. Congenital 
Toxoplasmosis (CT) occurs when the parasite is transferred from mother to 
child during pregnancy. Once a child is infected, it can lead to fetal death or 
several syndromes such as mental retardation, visual and hearing problems 133. 
A systematic review by Torgerson and Mastroiacovo estimates an incidence 
rate of 1.5 cases of CT per 1000 live births globally and the global burden for 
Toxoplasmosis calculated to be 1.2 million Disability-adjusted life year 
(DALY) per annum 134. DALY is a measure used by the World Health 
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Organization as a measure of disease burden and represents the sum of years 
lived with disability and years of life lost due to disease.    
 
A key ability for the parasite’s survival in humans would be its ability to 
encyst itself in the cells of host tissues in the bradyzoite stage. However, once 
the host becomes immunocompromised, the parasite can reconvert to its 
proliferative form (tachyzoites), reproducing clonally in the host. Thus, the 
immune system plays a huge part in clearing and keeping the parasite in 
check. Protective immunity against this apicomplexan parasite is dependent on 
cytotoxicity mediated by T cells and IFN-γ production 98,99, with CD8+ T cells 
being the major controller of the parasite and source of IFN-γ 135. In addition, 
the class I MHC H-2Ld is found to be essential for the control of toxoplasma 
replication in infected mice, further supporting the importance of CD8+ T cells 
in the control of disease progression 136. Several toxoplasma-specific natural 
antigens have also been identified and they include H-2Kb-restricted Tgd057 
137, H-2Ld restricted GRA6 138, GRA4 and ROP7 58.  
 
The high prevalence of Toxoplasma worldwide, its high global health burden, 
the crucial role CD8+ T cells play in controlling Toxoplasma infection and the 
availability of several of its natural Class I MHC-restricted antigens make it a 
good and important model to investigate how parasite-specific TCRs 
recognize their cognate pMHC ligands. This will allow better understanding of 
the immunity against this parasite as well as improve future 
immunotherapeutic approaches against it.  
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Recently, Kirak et. al. produced three transnuclear mice monoclonal for TCRs 
recognizing the Rop7 peptide antigen 61. Importantly, these TCRs were 
isolated at the peak of resolving the parasite’s infection, an accurate reflection 
of the physiological response of an infected host. Moreover, these three TCR 
clones were isolated from three different infected mice. Thus, they might give 
a glimpse of the differences, if any, between TCR usage among different 
individuals. We sought to recombinantly produce these three TCRs in a 
soluble form and characterize their binding affinities to the Rop7 peptide 
MHC. In addition, by generating these TCRs in a soluble form, other aspects 
such as how these TCRs bind to the same pMHC in a structural context and 
their use as therapeutic tools can be further explored in the future.   
 
 
2.2 Materials and Methods 
 
2.2.1 Cloning of TCR α and β chains. All TCR constructs were gene optimized 
for bacterial expression and cloned into pET28 expression vectors 
commercially (Genscript). Thr 157 and Ser 169 on the constant region of the α 
and β chain respectively were mutated to cysteine residues via PCR 
(Polymerase Chain Reaction) with complementary primers over the mutated 
sites. A sortase tag (LPETG) preceding a biotin tail (GLNDIFEAQKIEWHE) 
was also cloned into the C-terminal end of all the β chain constructs via PIPE 
(Polymerase Incomplete Primer Extension) 139. 
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2.2.2 Expression and purification of TCR α and β chains. Plasmids with the 
TCR α or β chain were transformed into BL21-DE3 strain of bacteria. Each 
batch of protein was prepared by growing up the bacteria in a 1 Litre (L) LB + 
Kanamycin culture and induced at mid log phase with 1 M IPTG (Isopropyl β-
D-1-thiogalactopyranoside) for 3 hours. The bacteria was then pelleted after 
induction and solubilized in solution buffer (50 mM Tris-HCl, 25% Sucrose, 1 
mM EDTA, pH 8.0) with 200 µL of 1 M DTT (Dithiothreitol), 100 µL of 
Lysozyme (50mg/ml), 50 µL of DNAse (10mg/ml), protease inhibitor tablets 
(Roche), 1 mM MgCl2 and incubated on ice for 30 minutes. Lysis buffer (50 
mM Tris-HCl, 100 mM NaCl, 1% Triton X-100, 1% Na deoxycholate, 1 mM 
EDTA, pH 8.0) was then added to the mix and incubated for a further 15 
minutes. 560 µL of 0.5 M EDTA was then added and the mixture was 
sonicated for complete cell lysis. The mixture was then pelleted down to yield 
the inclusion bodies. These inclusion bodies were then washed twice with 
Washing Buffer with Triton (50 mM Tris-HCl, 100 mM NaCl, 0.5% Triton X-
100, 1 mM EDTA, pH 8.0) and twice with Washing buffer without Triton (50 
mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 8.0). The washed inclusion 
bodies are then solubilized in Urea buffer (8M Urea, 25 mM MES, 10 mM 
EDTA, 0.1 mM DTT, pH 6.0) overnight at 4°C to yield the α or β chains.   
 
2.2.3 Refolding and purification of soluble TCRs. For a 1 L soluble TCR 
refold, 10 mg of α and β chain were mixed and injected into cold refold buffer 
(100 mM Tris, 400 mM L-Arginine, 2 mM EDTA, protease inhibitor (Roche), 
5 mM Reduced Glutathione, 0.5 mM Oxidized Glutathione, pH 8.0). 3 
injections were done in total with at least 8 hours of interval between each 
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injection, giving a total of 60 mg/L of proteins in the refold buffer. The 
refolded TCR is then concentrated down to a smaller volume before dialyzing 
with 20 mM Tris 50 mM NaCl for the next purification process via FPLC 
(Fast Protein Liquid Chromatography). The refolded TCR was purified by 
passing through a Superdex 200 size-exclusion column with 20mM Tris 
50mM NaCl. The salt in the buffer was then removed using a desalt column 
(Sephadex G25) with 20mM Tris. Lastly, the refolded TCR was isolated using 
a Mono Q anion exchange column with 20mM Tris as the running buffer and 
20mM Tris 1M NaCl as the elution buffer. Different elution gradients were 
created to elute the different TCRs.  
 
2.2.4 TCR-tetramer binding assay. In a 96 well filter plate (Millipore), 
streptavidin coated beads (Spherotech SVP-50-5) were incubated with 200 µL 
of blocking buffer (2% BSA (Bovine Serum Albumin) in PBS (Phosphate 
Buffer Saline)) for 20 minutes with shaking. The plate was then spun at 800 g 
for 2 minutes to remove the blocking buffer. Biotinylated TCRs were then 
captured on the beads by incubating them with beads resuspended in 50 µL of 
blocking buffer for 30 minutes with shaking. TCRs were added at least two 
times in excess of the number of binding sites on beads to ensure the beads 
were fully coated with the TCRs. The beads were then washed twice with 200 
µL of blocking buffer before incubating them with various concentrations of 
biotinylated pMHC coupled to streptavidin conjugated phycoerythrin (Strep-
PE) for 30 minutes with shaking. They were then washed twice with blocking 
buffer, fixed with 1% paraformaldehyde and analyzed using flow cytometry.    
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2.2.5 Surface Plasmon Resonance (SPR). The surface of a CM5 chip was first 
washed with 2 x 100 µL of (a) HCl (b) NaOH and (c) SDS. It is then activated 
with 35 µL of NHS (N-Hydroxysuccinimide) mixed with 35 µL of EDC 
(ethyl(dimethylaminopropyl) carbodiimide) for 7 minutes at a flow rate of 0.5 
µL/min. Streptavidin, mixed in immobilizing buffer (10 mM Na Acetate, pH 
5.0), was then immobilized on the chip covalently (~2000 RUs). 35 µL of 
ethanolamine was then flowed through the chip to block off excessive reactive 
groups. Next, 10 nM of biotinylated TCRs were flowed through the 
streptavidin-coated chip until ~500 RUs of TCR were immobilized on the 
chip. Binding analysis was carried out in running buffer (20 mM HEPES, 150 
mM NaCl, pH 7.4) by flowing various concentrations of pMHC through the 
chip. SPR for all clones were carried out in triplicates. The sigmoidal curves 
generated for each TCR clone are from equilibrium binding analysis fitted to a 
one-site specific binding model and are an average of 3 individual SPR runs 
with the graphical software Prism. The kinetic studies were carried out by 






2.3.1 Cloning, expression and purification of individual TCR chains 
 
There are several ways to produce recombinant proteins, some of which 
includes the use of bacteria, yeast, mammalian cell lines and insect cells 140. 
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The use of bacterial expression systems requires minimal technical expertise 
in terms of culture procedures and is relatively inexpensive. However, if the 
protein of interest is of non-bacterial origin, it will most likely be misfolded 
and shuttled to the inclusion bodies of the bacteria. The protein of interest 
must then be purified from the inclusion bodies before refolding them in vitro 
to yield the refolded protein. Different proteins require different refolding 
conditions so that acceptable amounts of correctly refolded proteins can be 
obtained 141,142. The TCR is a heterodimeric membrane-bound protein, 
consisting of an α and a β chain. In order to produce it as a soluble protein, its 
transmembrane domain is removed. The native TCR heterodimer is stabilized 
by a membrane proximal disulphide bridge but strategies to produce soluble 
TCRs by incorporating this bond has been unsuccessful 143. Several strategies 
to aid in the refolding of soluble TCRs have since been devised. They include 
refolding it as a single chain 101-103,144 or introducing jun/fos leucine zippers to 
the extracellular domains 106. A third method entails refolding TCRs by 
introducing a non-native disulphide bridge at the constant regions of both the 
α and β chains 107. This can be strategically achieved by mutating a threonine 
and a serine on the constant region of the α and β chain respectively to 
cysteines. These two residues were selected as they are not only similar to 
cysteine, they were observed in crystal structures to be in close proximity with 
side chains pointing towards each other. In addition, this strategy minimizes 
any changes to the constant regions of the TCRs and leaves their variable 
regions, which are important for recognition and binding to their cognate 
pMHC, untouched. With that, we have chosen this strategy to refold our 







Table 1. TCR gene usage. The various gene segments used in the recombination of the three 
TCR clones are indicated. It can be seen that all TCRs utilized different gene segments even 
though they have the same pMHC specificity. 
 
All three TCR clones of interest recognized the Rop7 peptide, from the 
parasite Toxoplasma gondii, presented by the mouse MHC H-2Ld. These three 
TCR clones utilize different α and β genes and will be termed Rop7c1, 
Rop7c2 and Rop7c3 (Table 1). Fig. 5A shows a general schematic of the α 
and β chains for the Rop7c1, Rop7c2 and Rop7c3 TCR clones. The native 
intra-chain disulfide bonds are shown in yellow and the non-native cysteines 
introduced at the constant regions are shown in red. We have also introduced a 
biotin tag on the β chain so as to allow for multimerization and binding to 
Surface Plasmon Resonance (SPR) chip surfaces for affinity characterization, 
as well as a sortase acceptor sequence, LPETG, before the biotin tag to allow 
for coupling of effector molecules 145. All mutations were verified to be 
correct by DNA sequencing. We then transformed the vectors encoding the 
individual TCR chains into BL21-DE3 bacterial cells for recombinant 
expression. After growing the bacteria to log phase, 1 M IPTG was added to 
induce the expression of the TCR chains. SDS-PAGE gels of bacterial cultures 
expressing the Rop7c1 TCR individual chains are shown in Fig. 5B. On the 
left panel, representative amounts of bacterial culture expressing Rop7c1α 
(O.D. ~ 0.3) before and after IPTG induction were run on a SDS-PAGE gel. 
Rop7c1α has a predicted molecular weight of ~ 22 kDa. Comparing pre (-) 
TCR α TCR β TCR V region J region V region D region J region 
Rop7c1 13D-1 30 13-1 1 1-1 
Rop7c2 13-1 31 13-2 2 2-7 
Rop7c3 7D-4 42 19 2 2-7 
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and post (+) IPTG induction, we observed a thick band between 20 and 25 
kDa, as indicated by the molecular weights standard (M), appearing in the post 
(+) IPTG induction lane. In addition, a band at the same position is seen from 
the final protein obtained from the solubilization of the inclusion bodies (IB). 
These results indicated that Rop7c1α was successfully produced by the 
bacteria. On the right panel of Fig. 5B, a thick band of molecular weight 
slightly above 25 kDa in the post (+) IPTG induction lane for Rop7c1β (~ 29 
kDa) and the protein purified from IBs also confirmed the production of 
Rop7c1β (Fig. 5B). Fig. 5C and D shows the SDS-PAGE gels for bacteria 
expressing the α and β chains of Rop7c2 and Rop7c3 respectively. All gels 
indicate the successful production and purification of both TCR chains.        
 
Figure 5. Construction of soluble TCR and expression of individual TCR chains. (A) 
Schematic showing the α and β chain constructs, the positions of the disulphide bridges, the 
LPETG sortase tag and the biotin tail. (B), (C) and (D) SDS-PAGE gels for bacteria 
expressing individual chains of Rop7c1, Rop7c2 and Rop7c3 TCRs respectively. Pre (-) and 
post (+) IPTG induction were shown with the final protein isolated from inclusion bodies 
(I.B.). A standards ladder indicating different molecular weights was loaded to confirm the 
size of the protein produced corresponded to that predicted for the individual TCR chains (M). 
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2.3.2 Refolding and purification of the 3 soluble TCR clones 
  
The Rop7c1, Rop7c2 and Rop7c3 TCRs were all refolded via a flash dilution 
method and dialyzed to remove additives in the refold buffer. The refolded 
TCRs were then concentrated down and biotinylated in vitro with the BirA 
enzyme. They were then purified by first passing it through a size exclusion 
column (S200) followed by an anion exchange column (MonoQ). The S200 
column separates proteins passed through by size with proteins of a larger 
molecular weight being eluted first and proteins with smaller molecular 
weights eluted later. After passing the Rop7c1 TCR through the S200 column, 
we observed three peaks (Fig. 6A). The first peak corresponded to a molecular 
weight of above 400 kDa, as estimated from a run of protein standards, and 
most likely belonged to the soluble aggregates generated during the refolding 
process. The second peak, indicated by an asterix, corresponded to a 
molecular weight of approximately 50 kDa and is the peak of interest as the 
refolded TCR has a molecular weight of approximately 50 kDa. The third 
peak most likely indicates the elution of salts in the buffer as no bands were 
seen when this fraction was run on a SDS-PAGE gel (not shown). Fractions 
from the second peak of the S200 were then collected, desalted (Fig. 6B) and 
passed through MonoQ, an anion exchange column which separates proteins 
by charge via an increasing salt concentration. The soluble TCRs were 
predicted to be negatively charged based on their P.I. (isoelectric point) in the 
running buffer used and thus, an anion exchange column was selected as the 
choice of separation. A single major peak can be seen in the MonoQ 
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chromatogram (Fig. 6C) and its fractions were analyzed by SDS-PAGE gels 
under reducing and non-reducing conditions (Fig. 6D).  
 
 
Figure 6. Purification of soluble Rop7c1 TCRs. (A) Size exclusion chromatography (S200) 
of Rop7c1 TCR. The peak corresponding to the refolded TCR is indicated by an asterix. (B) 
The refolded TCR is then buffer-exchanged to remove the salt in the original buffer for 
subsequent purification step. The orange peak corresponds to the elution of salt in the buffer. 
(C) Charge separation chromatography (Mono Q) of Rop7c1 TCR. The soluble Rop7c1 TCR 
was eluted with an increasing concentration of 20 mM Tris 1 M NaCl on an anion exchange 
column after size exclusion purification. (D) SDS PAGE gel showing the individual chains 
under reducing (+DTT) conditions and a disulphide bridge linked α and β chains band under 
non-reducing (-DTT) conditions. Soluble Rop7c1 TCRs are also shown to be fully 
biotinylated as they bind to streptavidin completely. 
 
In the presence (+) of the reducing agent DTT (dithiothreitol), we see two 
bands corresponding to the molecular weights of both the α and β chains of the 
TCR. The I.B. purified α and β chains were also individually loaded on the gel 
(α and β) to confirm the identities of the two bands seen in the collected 
fractions. In the absence (-) of DTT, a single band of approximately 50 kDa is 
seen. This is because under non-reducing conditions, the α and β chains are 
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still connected by the non-native disulphide bridge and thus, a single band 
corresponding to approximately the combined molecular weight of the TCR is 
seen. In addition, we investigated the extent of the Rop7c1 TCR biotinylation 
status after in vitro biotinylation. We mixed excess amounts of soluble 
streptavidin with the Rop7c1 TCR and ran it with SDS-PAGE (Fig. 6D). From 
the gel, it can be seen that in the TCR + Strep lane, the Rop7c1 TCR band is 
missing. Instead, we see a streptavidin band and 2 other higher molecular 
weight bands. This indicates that all the Rop7c1 TCR has bound to the 
streptavidin added. Streptavidin has four binding sites for biotinylated 
substrates and weighs around 60kDa. Thus, the band with a molecular weight 
between 100 kDa And 150 kDa should indicate streptavidin molecules binding 
to one TCR. On the other hand, the band between 150 kDa to 200 kDa should 
represent streptavidin binding to two TCRs. For a one litre refold, 
approximately 0.9 mg of purified Rop7c1 TCR can be obtained. 
 
Similarly, the Rop7c2 TCR was purified via the same way (Fig. 7). After in 
vitro biotinylation, the refolded Rop7c2 TCR was passed through a size 
exclusion column (Fig. 7A). As expected, a peak, as indicated by an asterix, 
was observed at a molecular weight of approximately 50 kDa. The protein 
collected was then desalted (Fig. 7B), before passing through Mono Q (Fig. 
7C). After the characterization of the various proteins eluted from MonoQ, we 
identified the salt concentration in which the refolded Rop7c2 TCR elutes at 
(asterix on Fig. 7C). We then ran the fractions collected with SDS-PAGE 
(Fig. 7D) and observed that in the presence (+) of DTT, two bands 
corresponding to the α and β chain are observed. However, under non-
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reducing conditions (-), other than a band corresponding to the combined 
molecular weight of both the α and β chains, another band corresponding to 






Figure 7. Purification of soluble Rop7c2 TCRs. (A) Size exclusion chromatography (S200) 
of Rop7c2 TCR. The peak corresponding to the refolded TCR is indicated by an asterix. (B) 
The refolded TCR is then buffer-exchanged to remove the salt in the original buffer for 
subsequent purification step, with an asterix marking the refolded TCR and the salt peak 
(orange) eluting later (C) Charge separation chromatography (Mono Q) of Rop7c2 TCR. The 
soluble Rop7c2 TCR (asterix) was eluted with an increasing concentration of 20 mM Tris 1 M 
NaCl on an anion exchange column after size exclusion purification. (D) SDS PAGE gel 
showing the Mono Q purified protein (*) contains the individual α and β chains under 
reducing (+DTT) conditions. However, under non-reducing conditions (-DTT), two bands are 
observed, the refolded heterodimer and and an unpaired β chain. (E) Another round of size 
exclusion chromatography (S75) of the Mono Q purified fractions yielded three peaks (F) 
SDS PAGE analysis of the peaks (P1 and P2), excluding the aggregate peak, shows that the β 
chain has been isolated from the refolded Rop7c2 TCR. (G) Soluble Rop7c2 TCRs are also 
shown to be fully biotinylated as they bind to streptavidin completely. 
 
 
Two possibilities could be envisioned in this scenario: one, the β chain possess 
a similar charge to the refolded TCR and thus, got eluted at the same salt 
concentration; two, the β chain sticks non-specifically to the refolded TCR. 
The P.I. of the Rop7c2 TCR is estimated to be approximately 6 whilst that of 
the β chain alone is approximately 6.3. Thus, it may be possible that the two 
proteins are eluted together in the Mono Q step. Since the size of the refolded 
TCR (~ 50 kDa) is much larger than the size of the β chain alone (~ 29 kDa), 
we thought it might be possible to separate the two via a size exclusion 
column. Thus, after the MonoQ step, we passed the fractions collected through 
a Superdex75 column (S75), a column that provides better resolution for 
separation of proteins with smaller molecular weights as compared to the S200 
column (Fig. 7E). A total of three peaks can be seen. The first peak 
corresponds to a size of greater than 450 kDa and should be aggregates 
generated from the handling of the protein. The second peak (P1) elutes at 
close to 60 ml and corresponds to a molecular weight of approximately 50 
kDa and should be the refolded Rop7c2 TCR. The third peak (P2) appears 
almost immediately after and corresponds to a molecular weight smaller than 
 47	  
44 kDa and is most likely the β chain alone. We then ran the fractions from 
the second and third peak of the refolded Rop7c2 TCR with SDS-PAGE (Fig. 
7F). From the gel, we see that under reducing conditions, the α and the β 
chains are present in almost equal amounts and under non-reducing 
conditions, only a single band corresponding to the molecular weight of the 
Rop7c2 TCR is seen. In addition, the third peak consists only of the β chain as 
expected. Thus, the S75 column has successfully isolated the purified Rop7c2 
TCR from its β chain. A check on its biotinylation status also indicated that all 
the Rop7c2 TCRs have been biotinylated (Fig. 7G). For a one litre refold, 
approximately 0.4 mg of refolded Rop7c2 TCR can be obtained.          
 
 
Figure 8. Purification of soluble Rop7c3 TCRs. (A) Size exclusion chromatography (S200) 
of Rop7c3 TCR. The peak corresponding to the refolded TCR is indicated by an asterix. (B) 
The refolded TCR is then buffer-exchanged to remove the salt in the original buffer for 
subsequent purification step with the refolded TCR indicated by an asterix and the salt from 
the buffer eluting later (orange). (C) Charge separation chromatography (Mono Q) of Rop7c3 
TCR. The soluble Rop7c3 TCR was eluted with an increasing concentration of 20 mM 
phosphate buffer 1 M NaCl on an anion exchange column after size exclusion purification. 
(D) SDS PAGE gel showing the individual chains under reducing (+DTT) conditions and a 
disulphide bridge linked α and β chains band under non-reducing (-DTT) conditions. Soluble 
Rop7c3 TCRs are also shown to be fully biotinylated as they bind to streptavidin completely. 
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The Rop7c3 TCR was also refolded and passed through the S200 column (Fig. 
8A), desalted (Fig. 8B) and lastly purified with MonoQ (Fig. 8C). SDS-PAGE 
was used to confirm the identity of the MonoQ purified protein and its fully 
biotinylated status (Fig. 8D). The refolding yield for the Rop7c3 TCR was the 
lowest among the three clones with approximately 0.05mg of TCR obtained 
per litre of refold.  
 
2.3.3 Binding specificities of refolded TCRs 
 
Although the SDS PAGE gels indicate purity of all three TCR clones, it 
remains to be determined if the TCRs are correctly refolded i.e. they can 
recognize specifically their cognate pMHC. TCRs usually bind to their 
cognate pMHC with weak affinity (Kd ~ 1 – 100 µM) 146. Thus, detecting such 
a weak interaction may be difficult. However, multimerization of one of the 
binding partners can increase the binding between TCR and pMHC via 
avidity. Altman et. al. had successfully utilized this approach to create pMHC 
tetramers and identify antigen specific T cells 55. Multimerized TCRs have 
also been shown to be able to stain tumour cells and quantify pMHC 
complexes on cell surfaces 147. To test if the refolded TCRs could recognize 
their pMHCs, we first bound the individual biotinylated TCR clones to 
streptavidin coated flow cytometry beads (Spherotech). We then generated H-
2Ld Rop7 pMHC tetramers fluorescent in phycoerythrin (PE) by mixing 
biotinylated soluble Rop7 MHC molecules with commercially available 
streptavidin coated PE. If the TCRs are correctly refolded, they will bind to 
the pMHC tetramers and fluoresce in the PE channel. 
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We incubated titrating concentrations of PE tagged pMHC tetramers with 
TCR coated beads and analyzed their bindings with flow cytometry (Fig. 9). 
Looking at the Rop7c1 TCR, we observed that the TCR binds strongly to 0.31 
µM of Ld Rop7 pMHC tetramers, with as little as 0.31 nM of tetramers needed 
to bind to the TCR (Fig. 9A). 
 
 
Figure 9. Functional avidity of the TCR tetramers to Ld Rop7 pMHC. Streptavidin coated 
beads were saturated with (A) Rop7c1 TCR, (B) Rop7c2 TCR and (C) Rop7c3 TCR and 
stained with titrating amounts of Ld Rop7 pMHC tetramers conjugated to PE. The Ld Gra4 
pMHC tetramer was included as a negative control. (D) The binding avidities of the three 
TCR clones are graphically represented with the Rop7c1 exhibiting the highest functional 
avidity amongst the three and Rop7c2 TCR the lowest. All measurements were made with the 
same batch of Ld Rop7 MHC – PE tetramers. 
 
As expected, with the amount of pMHC tetramers decreasing, the intensity of 
the PE fluorescence decreases as well. Most importantly, the Rop7c1 TCR 
does not bind to pMHC tetramers presenting the Gra4 peptide, another 
Toxoplasma derived peptide also restricted by H-2Ld. Thus, the Rop7c1 TCR 
is specific for its cognate pMHC and is correctly refolded. Similarly, Rop7c2 
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TCR (Fig 9B) and Rop7c3 TCR (Fig. 9C) showed that they can bind and are 
specific for the H-2Ld Rop7 MHC tetramers, indicating that they are correctly 
refolded as well. However, it was obvious that different amounts of pMHC 
tetramers bound to each of the TCR clones, even though the same amount was 
added, hinting at a possible difference in binding affinity for the pMHC 
between the three clones. We then compared the binding avidities of the three 
TCR clones by plotting the median fluorescence intensity detected against the 
amount of pMHC tetramers added (Fig. 6D). It can be seen that the Rop7c1 
TCR binds with the highest avidity, followed by the Rop7c3 TCR and lastly, 
the Rop7c2 TCR binds with the least avidity. It should be noted that checking 
the non-specific binding of pMHC tetramers to the empty streptavidin coated 
flow cytometry beads would be a good control. However, since all flow 
cytometry beads were saturated with TCRs, we believe that there will be 
minimal non-specific binding by the pMHC tetramers to the beads. Any non-
specific binding will be reflected in the staining with the negative control, Ld 
Gra4 MHC tetramer, of which minimal staining is observed.  
 
With the three TCR clones correctly refolded and specific for their cognate 
pMHC, we moved on to further characterize their binding affinities to the H-







2.3.4 Binding affinity between the three TCRs and Ld Rop7 MHC 
 
The binding affinity of a TCR to its cognate pMHC plays a huge role in the 
activity and specificity of the T cell which expresses it 148. Binding parameters 
such as association rates 149 and dissociation rates 150 have been shown to be 
important in T cell activation. Changes in sensitivity towards antigen have 
also been shown to affect functions of T cells as well 151. In addition, current 
models on T cell activation, such as the serial triggering hypothesis 152 and 
kinetic proof-reading model 150, are dependent on the binding affinities of the 
TCRs to a certain extent as well. Thus, looking at the binding affinities of 
these three TCR clones against the same pMHC will allow us to gain more 
understanding on T cell immunity against Toxoplasma. 
 
We characterized the binding affinities of the TCRs to H-2Ld Rop7 pMHC 
with Surface Plasmon Resonance (SPR), a method widely used in 
characterizing binding kinetics between solution phase ligands and 
immobilized receptors without any need for labels. Since the first use of SPR 
to study TCR-pMHC interactions, several studies have caught onto the trend 
and used it to characterize both TCR-pMHC interactions and other 
macromolecular interactions with their ligands 153,154. 
 
We first immobilized the biotinylated TCRs to a streptavidin coated chip and 
flowed various concentrations of pMHC through. Since it is possible the 
peptide might fall off the MHC molecule, we chose to bind the TCR on the 
chip so as to keep the pMHC on ice as long as possible, minimizing the 
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amount of peptide free MHCs that flow through the chip. SPR detects changes 
in the refractive index on the chip surface as protein molecules bind to those 
immobilized on the chip. This is reflected as a change in the resonance units 
(RUs) on the instrument. Sensorgrams are generated during the experiment 
and they typically consist of three phases namely an association phase, an 
equilibrium phase and a dissociation phase.  
 
 
Figure 10. Binding affinities of the TCR clones to Ld Rop7 MHC. Surface Plasmon 
Resonance (SPR) sensorgrams of (A) Rop7c1, (C) Rop7c2 and (E) Rop7c3 bound with 
various concentrations (1µM – 150µM) of Ld Rop7 MHC. Equilibrium analysis of the SPR 
data for (B) Rop7c1, (D) Rop7c2 and (F) Rop7c3 were carried out with the graphical software 
Graphpad Prism and analyzed with a one-site specific binding model. The binding affinity 
constant for each TCR is an average of three experiments. 
 53	  
During the association phase, there is an increase in the RUs and its rate of 
increase is dependent on how fast the pMHCs bind to the TCRs bound on the 
chip. An equilibrium phase is then reached when there is no overall change in 
RUs and this can be interpreted as pMHCs associating with and dissociating 
from TCRs at the same rate. Last, the dissociation phase occurs when there is 
a decrease in RUs and the rate of decrease is dependent on how fast the 
pMHCs fall off the TCRs.The SPR sensorgrams for TCRs Rop7c1 (Fig. 10A), 
Rop7c2 (Fig. 10C) and Rop7c3 (Fig. 10E) are shown. From the sensorgrams, 
the equilibrium RU (RUeqm) is determined and plotted against the 
concentration of pMHC flowed through to yield a sigmoidal curve for Rop7c1 
(Fig. 10B), Rop7c2 (Fig. 10D) and Rop7c3 (Fig. 10F) using the graphical 
software Prism.  
 
 
Figure 11. Kinetic analysis of the TCR clones binding to the Ld Rop7 MHC. The 
sensorgrams for (A) Rop7c1, (B) Rop7c2 and (C) Rop7c3 were analyzed using a global fit 
algorithm with the BIAevaluation software, assuming a 1:1 Langmuir binding. The various 
kinetic constants are tabulated and shown on the bottom right.  
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These curves can then be fitted to determine the dissociation constant for the 
TCR binding to the pMHC. From the curves, the Rop7c1 TCR has the 
smallest dissociation constant at ~ 4 µM, followed by Rop7c3 (~ 30 µM) and 
lastly, Rop7c2 (~ 105 µM). This would indicate that Rop7c1 TCR binds most 
strongly to the H-2Ld Rop7 pMHC, followed by Rop7c3 TCR and Rop7c2 
TCR binds most weakly. This hierarchy of binding between these three TCR 
clones is in line with that which we saw in the functional avidity experiments 
mentioned earlier.   
 
Other than determining the dissociation constants for the TCRs, kinetic 
analysis can also be carried out with the SPR sensorgrams. Curve fitting can 
be carried out on the sensorgrams (Fig.11) and kinetic values such as 
association and dissociation rates can be estimated (Fig. 11). From these 
values, we can see that Rop7c1 TCR binds with a high association rate, 
approximately sixty-five times more than that of the Rop7c2 TCR (2.2 x 105 
M-1s-1 vs 3.4 x 103 M-1s-1). Although the Rop7c2 TCR binds longer to H-2Ld 
Rop7 MHC, dissociating at approximately a third of the rate as compared to 
the Rop7c1 TCR (0.35 s-1 vs 1.03 s-1), the much higher association rate for 
Rop7c1 TCR allows it to bind with a higher affinity as compared to the 
Rop7c2 TCR. On the other hand, the Rop7c3 TCR, with an intermediate 
binding affinity compared to the other two TCRs (Kd = ~30 µM), binds with 
an association rate approximately ten fold lower than the Rop7c1 TCR but 
approximately six fold larger than Rop7c2 TCR. Its rate of dissociation (0.56 
s-1) is also between that of Rop7c1 and Rop7c2 TCR. Thus, it would seem that 
all three TCR clones, though similarly isolated during the peak response to a 
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Three mouse TCR clones specific for the Rop7 antigenic peptide from the 
parasite Toxoplasma gondii were isolated 61. To understand more about T cell 
immunity against this parasite, we generated soluble forms of these three 
TCRs. These TCRs were heterodimeric in structure, like that of membrane-
bound TCRs, and joined by a non-native disulfide bond in their constant 
regions. With these soluble TCRs, we assayed their binding affinities to the 
same pMHC, H-2Ld Rop7. These three TCR clones bound to their cognate 
pMHC with different binding affinities (Fig. 10), within the range of binding 
affinities observed for wild-type TCRs thus far (1 µM – 100 µM) 3. In 
addition, the association rates, dissociation rates and half-lives of these three 
TCR clones also differ from each other but are within the range of that seen 
for various TCR – pMHC (agonists) interactions reported 148.  
 
TCR binding affinity and kinetics have a huge impact on T cell activation.  
Several models for T cell activation exist of which two shall be discussed 
here. First, the serial triggering hypothesis proposes that each pMHC must be 
able to trigger a large number of TCRs in successive rounds. Valitutti et. al. 
has shown that even with a small amount of pMHC expressed, approximately 
100 per APC (Antigen Presenting Cell), up to 18,000 TCR molecules are 
activated 152. They have also observed that sustained signaling results from the 
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prolonged and uninterrupted binding between the TCR and the pMHC 155. 
Thus, combining these observations, the serial triggering model was proposed 
for T cell activation. This model would predict TCRs to have a high 
association rate and a fast off rate, allowing them to dissociate from pMHCs 
quickly upon binding and allowing the next TCR to bind. In addition, it was 
also proposed that there should be a defined window of half life for optimal 
binding as TCRs which dissociates too fast prevent productive TCR activation 
and those that falls off too slow reduce the efficiency of serial triggering 156. In 
addition, other evidences have surfaced as well to support this model. Irvine 
et. al. showed that as few as 10 – 15 pMHC complexes are sufficient to 
activate and sustain signaling in CD4+ T cells 157. Recent data from Mark 
Davis’ lab have also lent support to the serial triggering model as they 
observed that a single pMHC molecule was sufficient to induce the formation 
of TCR clusters in the immunological synapse, activating the T cells. Despite 
so, exceptions to the serial triggering model do exist and have been 
exemplified by engineered mutant TCRs which could bind to their cognate 
pMHCs with high binding affinities and very long half-lives 158,159.  
 
On the other hand, the kinetic proofreading model proposes that upon intital 
binding between the TCR and its cognate pMHC, a series of intermediates are 
generated before the final active complex is formed 150. In the case of an 
antagonistic peptide, the TCR dissociates from the pMHC after binding, 
leading to a reversal of the modifications. Thus, the rate of dissociation of the 
TCR from the pMHC plays a huge role in this model as if the TCR does not 
bind long enough to the pMHC, the series of intermediates before the final 
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activated complex cannot be generated. Thus, a minimal half-life for the TCR 
binding to the pMHC is required for a productive TCR signal. Kalergis et. al. 
reported that increasing or decreasing the stability of the interaction with the 
TCR affected the activation status of the TCR, further proposing that optimal 
T cell activation occurs within a distinct range of half-life for TCR binding to 
pMHC 160. However, as the results were obtained with pMHC tetramers, the 
absolute values of dwell time were in the order of minutes, and do not reflect 
that of monomeric TCRs binding to monomeric pMHCs. In addition, 
Rabinowitz et. al. also proposed a similar model, known as the kinetic 
discrimination model, where TCRs need to bind to their cognate pMHC for a 
sufficiently long enough time before activation of T cells can occur 161. 
However, it differs from the kinetic proofreading model in that it proposes that 
the ratio of positive to negative signals generated during TCR – pMHC 
binding can distinguish agonist and antagonist peptide in a single step as 
opposed to several steps required for the kinetic proofreading model.   
 
Although there are no definitive proofs for these models, all proposed the 
presence of an optimal range of contact or dwell time for TCRs to pMHCs for 
activation to take place. The Rop7c1 TCR appears to fit the criteria for the 
serial triggering model, binding with a high association rate of 2.2 x 105 M-1s-1 
and dissociating rapidly from the pMHC at a rate of 1.03 s-1. However, the 
Rop7c2 TCR binds with a much slower association rate (3.4 x 103 M-1s-1) and 
dissociates at a rate three-fold lower than Rop7c1 TCR (0.35 s-1). In this case, 
it is a huge contrast from the Rop7c1 TCR with a sixty-five fold difference in 
association rate. The Rop7c3 TCR binds with kinetics intermediate to these 
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two TCRs. These data seemed to support the presence of a range for dwell 
time as well since all three TCRs were able to activate their respective T cells 
upon binding to the same pMHC, even though their half-lives were different 
(Fig. 11). In addition, the binding kinetics observed were also in line with a 
study done by Cole et. al. where they compared the binding kinetics of several 
human TCRs to their cognate pMHC 162. Amongst their conclusions included 
the observation of varied association rates between the different TCRs and a 
small difference between their dissociation rates, both of which coincide with 
what we observe with the Rop7 TCRs.  
 
Several studies on different TCRs binding to the same pMHC have also been 
done thus far. Gras et. al. characterized the structures of three different human 
TCRs recognizing an immunodominant EBV  antigen restricted by HLA-B8. 
These three TCRs bound to their cognate pMHC with a smaller difference in 
binding affinity (8 µM – 31 µM) as compared to the Rop7 specific TCRs 163. 
In addition, the group of Brian Baker also characterized two human TCRs, the 
A6 and the B7, against the HLA-A2 restricted Tax peptide. These two TCRs 
bind with nearly identical affinities and kinetics 164. One caveat of these 
studies is that the TCRs used in these studies were selected and thus may be 
biased. The Rop7 specific TCRs, on the other hand, were isolated during the 
peak of an infection and thus, indicate that under physiological conditions, T 
cells expressing TCRs with a range of binding affinities are activated. This 
may imply that factors, other than binding affinity, play a role in the activation 
of antigen specific T cells. Evidence for this can be seen in the A6 and B7 
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TCR pair where even though they bind with similar affinity and kinetics, they 
recognize their cognate pMHC differently thermodynamically 164.  
 
In conclusion, we have produced three correctly refolded TCR clones specific 
for a particular pMHC. These TCRs were isolated during the peak of an 
immune response against the parasite Toxoplasma gondii in an in vivo setting. 
Characterization of the binding affinities and kinetics of these TCRs seem to 
propose that activated T cells bind with a range of binding affinities and that a 
range exist for the dwell time required for activation to take place. With no 
direct correlation between binding affinity and activation of T cells seen with 
these three TCRs, it implies the presence of other factors which may play a 
role in antigen specific T cell activation. It will also be insightful to compare 
the function of these three T cell clones and investigate if there is any 
correlation between function and binding affinity. We will further explore this 
















Substantial studies have developed several applications for soluble TCRs. 
Against tumours, soluble TCRs can be tagged to toxins to directly kill APCs 
expressing the target peptide 93. In addition, they can be tagged to cytokines 
such as IL-2 to elicit an indirect effect, directing effector T cells to the target 
cells and stimulating the proliferation of the effector cells. This was shown to 
reduce lung metastases and tumour growth in a mouse model 94,105. With that, 
soluble TCRs tagged to IL-2, and recently IL-15, have been developed as 
cancer therapeutics by a commercial company and undergoing clinical trials 
(www.altorbioscience.com). Soluble TCRs can also be used to inhibit 
activation of Cytotoxic T Lymphocytes (CTLs). Laugel et. al. produced 
multimerized soluble TCRs specific for the HLA-A2 restricted human T cell 
leukemia virus type I Tax epitope and found that when pre-incubated with 
APCs presenting the Tax peptide, they were able to inhibit activation of  Tax-
specific CTLs 28. Thus, it can be envisioned that soluble TCRs can be used as 
inhibitors against autoimmune T cells in diseases such as Type I diabetes. 
Soluble TCRs have also been shown to be able to stain human tumours, 
allowing for the imaging of tumours and quantification of tumour specific 
epitopes 147,165. Despite the many potential therapeutic applications for soluble 
TCRs, its development has been slow with few moving on to clinical trials. 
The main reason is the challenges faced in the production of these soluble 
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TCRs. Being membrane-bound molecules, heterodimeric soluble TCRs are 
unstable in the soluble form and they tend to aggregate. 
 
Protein aggregation can cause several problems. First, aggregation reduces the 
yield of recombinant protein production. Soluble TCRs are largely generated 
recombinantly 28,147,165 and thus, low protein yields would translate to longer 
time and large amounts of input materials being required in order to generate 
enough refolded TCRs for their various applications. Second, aggregated 
proteins can cause several neurodegenerative diseases such as Alzheimer’s, 
Parkinson’s and Huntington Disease. These diseases are caused by the 
misfolding and subsequent aggregation of disease-related proteins into 
amyloid fibrils. These fibrils, also known as prions, are infectious and can 
cause the same disease if passed on to another individual. As more research on 
them is being done, it became apparent that the ability to form fibrils is not 
limited to proteins specific to these neurodegenerative diseases but may be an 
inherent property of all polypeptide chains 166. Although it is not clear how the 
fibrils damage the cells, it is very likely that these aggregated proteins impair 
cell function by interacting with cellular components 167. For example, 
misfolded and aggregated proteins can have hydrophobic regions exposed and 
these regions can interact with cell membranes, disrupting their stabilities and 
possibly permeabilizing them, leading to cell death.  
 
Several examples of non-neurodegenerative diseases caused by protein 
aggregation also exist of which two include systemic amyloidoses and type II 
diabetes 168,169. Primary systemic amyloidosis is caused by the aggregation of 
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the light chains of Immunoglobulins. TCRs also possess immunoglobulin 
folds and thus, there is a chance for unstable soluble TCRs to aggregate, form 
amyloid fibrils and cause systemic amyloidosis eventually. Several other 
proteins, such as β2-microglobulin and lysozyme, have also been shown to be 
able to aggregate due to several reasons, such as mutations or misprocessing in 
the cell, and without proper clearance, they can also form amyloid fibrils and 
cause diseases 166. To date, no obvious similarities between the various 
peptides or proteins causing amyloid diseases have been observed. However, 
all amyloid fibrils have been shown to contain a high content of β structure, 
even if the original protein or peptide is rich in α-helical structure 166. Thus, it 
is possible that soluble TCRs, which contain several α helices, can also form 
amyloid fibrils upon aggregation.  
 
To realize the many potential applications of soluble TCRs, it is important to 
reduce, if not prevent, their aggregation in solution. As a therapeutic tool, 
preventing aggregation can improve the bioavailability and consistency of 
soluble TCRs. In addition, immunogenicity against aggregated TCRs can be 
curbed and their production yield and shelf lives can be further improved 170. 
To do so, one can look at how protein folds. Several hypotheses have been 
proposed for the process of protein folding. The hydrophobic collapse is one 
model where it proposes that proteins fold with hydrophobic side chains of 
amino acid residues buried in a hydrophobic core, whilst the charged side 
chains are exposed. This would allow the protein to be stable in aqueous 
solutions with the packing of the hydrophobic core and the formation of 
hydrogen bonds, disulfide and salt bridges 171. The observation that the net 
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charge of a protein correlates with its solubility i.e. proteins are least soluble at 
their isoelectric point, where they bear a net charge of zero, lends further 
credit to this model 114. A class of unfolded proteins that do not cause diseases 
in the cell, also known as intrinsically disordered proteins, tend to have large 
net charges, possibly implying that high net charges may prevent aggregation 
118,119. This notion was also supported by Simeonov et. al., where they showed 
that increasing the net charge of human enteropeptidase light chain improved 
its stability 172. This could be due to the larger number of charges causing 
repulsion between molecules when the protein is unfolded, thus disfavoring 
aggregation. A study by Chiti et. al. also show that aggregation tendencies 
among peptide variants can be predicted from their differences in net charges 
173. From these evidences, it seems to imply that increasing the net charges of 
proteins can improve their stabilities and disfavor aggregation.  
 
Recently, several studies have shown that increasing the net charge on the 
surfaces of proteins can reduce their propensity to aggregate. The group of 
David Liu has shown that by increasing the surface charges of Green 
Fluorescent Protein (GFP), a process they coined “supercharging”, GFP 
became resistant to aggregation not only to thermal but also to chemical 
denaturation. In addition, these highly charged GFP remains fully fluorescent 
109. Similar results were also seen when the net charge was increased for two 
other proteins, Glutathione-S-Transferase (GST) and Streptavidin. Thus, it 
will seem that “supercharging” proteins can improve the stabilities of protein 
and prevent aggregation but with minimal impact to their functions. Next, 
David Liu’s group moved on to show that by using the highly positively 
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charged GFP molecules, they could use it as a vehicle to deliver siRNA into 
cells 121. Moreover, they observed that the supercharged GFP is stable in 
serum and has a prolonged half-life as well. Other than GFP, several other 
proteins have also shown better stability with “supercharging” as well. Miklos 
et. al. have shown that by “supercharging” single chain antibodies, they not 
only increased the thermostabilities of the antibodies, some exhibit increased 
binding affinities to their cognate ligands as well 108. Thus, it seems that this 
strategy can be applied to several different types of proteins.  
 
With this in mind, we sought to investigate if “supercharging” soluble TCRs 
would similarly lead to an increase in stability and thus, reducing their 
propensity to aggregate. We decided to employ an algorithm used by the 
group of David Liu, the AvNAPSA (Average number of Neighboring Atoms 
Per Side-chain Atom), to redesign the TCR clone, Rop7c1, increasing its net 
charge and investigating if it will result in increased stability. The AvNAPSA 
program identifies amino acid residues that are solvent exposed. Together with 
the coordinates from the crystal structure of the protein, the AvNAPSA 
assigns a score to each amino acid residue. A low AvNAPSA score would 
indicate that a given residue has few non-self atoms around it, indicating that 
it most probably is solvent exposed 109. Targeting these residues with low 
AvNAPSA values for mutation would decrease the likelihood of changes 




In Chapter 2, the Rop7c1 TCR was identified to possess the highest binding 
affinity to the Ld Rop7 MHC amongst the three TCR clones. Thus, it would be 
an attractive tool for further development as a targeting molecule. After 
solving the crystal structure of the soluble Rop7c1 TCR with our collaborator, 
we used the AvNAPSA program to generate variants with increased net 
charges and investigated if their stabilities are improved as compared to the 
wild-type TCR. 
 
3.2 Materials and Methods 
 
3.2.1 Design of supercharged Rop7c1 TCR chains. The AvNAPSA program 
was kindly supplied by David Liu’s group and used with the crystal structure 
data of the Rop7c1 TCR to generate an AvNAPSA score for all the amino acid 
residues. All residues were then sorted from the most solvent-exposed to the 
least based on their scores. Charged or polar amino acid residues (DERKNQ) 
were then selected and mutated either to Asp or Glu for negative 
supercharging. To choose which of the two residue (Asp/Glu) to mutate to, we 
employed the online prediction server Rosetta.design 174 which selects 
mutations that pack well with the original protein backbone structure. To this 
end, the α and β chain sequences were submitted to the Rosetta server as a 
dimer with only the selected solvent exposed amino acid resiudes allowed to 
change to either Asp or Glu for negative supercharging. Similarly, the same 
procedures were used for positive supercharging except the selected amino 
acid residues are mutated to either Lys or Arg. 
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3.2.2 Production and purification of supercharged TCR chains. The 
supercharged Rop7c1α and Rop7c1β chains were cloned into pET 28(a) 
vectors and codon optimized for bacteria expression commercially 
(GenScript). All sequences were verified upon receiving the plasmids. These 
vectors were then transformed into the BL21-DE3 strain of bacteria for protein 
expression. Each batch of proteins was then produced via large scale induction 
of bacteria culture and the subsequent purification of the inclusion bodies as 
detailed above.  
 
3.2.3 Refolding of supercharged TCRs. Supercharged TCRs were refolded in a 
similar fashion as that of the wild-type TCRs as detailed above. Briefly, 10mg 
of α chain and 10 mg of β chain were mixed and injected into 1 L of cold 
refold buffer. A total of 3 injections were made with at least 8 hours in 
between with a final protein concentration of 60 mg/L. The refold buffer 
containing the refolded TCR was then concentrated down and dialyzed in 20 
mM Tris 50 mM NaCl before undergoing purification steps by FPLC. Size 
exclusion, followed by desalting and lastly, anion or cation exchange 
chromatography, depending on the final charge of the TCR were typically 
used to isolate the refolded TCR. 
 
3.2.4 Assessing functional avidities of supercharged TCRs. These experiments 
were carried out in a similar fashion as the TCR-tetramer binding assays in the 
previous chapter. Briefly, streptavidin coated flow cytometry beads were 
incubated with blocking buffer (2% BSA in PBS) before adding biotinylated 
TCRs in excess. The TCR coated beads were then washed to remove unbound 
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TCRs before incubating them with various concentrations of biotinylated 
pMHC coupled to Strep-PE. They were then washed and fixed with 1% 
paraformaldehyde (PFA) before analysis with flow cytometry.    
 
3.2.5 RAW cells staining with TCR tetramers. 1x106 RAW cells were 
incubated with 105 µM of Gra4 or Rop7 peptide for 1 hour at 37°C. They 
were then washed once with PBS before incubated with Live/Dead stains 
(Molecular Probes L10119) for 15 minutes. The cells were then washed once 
with PBS before incubating with 2 µM of TCR tetramers for 1 hour on ice. 
The cells were then washed twice with PBS before fixing with 1% PFA. The 
fixed cells were then analyzed by flow cytometry. Stainings with each TCR 
tetramer clone were at least duplicated.  
 
3.2.6 Stability assay of supercharged TCRs. 10 µM of supercharged TCRs 
were mixed with the respective buffers before 1 µL of 25x diluted SyPro 
Orange dye (Molecular Probes S-6650) was added to a final reaction volume 
of 40 µL. The experiment was then carried out with a 7500 Fast Real Time 
PCR System (Applied Biosystems) and the samples subjected to a heating 
cycle from 25°C to 99°C with a 1% gradient using the ROX filter as a readout. 
The raw melt curves were then analyzed with the graphical software PRISM, 
where the first derivatives of the raw melt curves for each supercharged TCR 
in each condition were generated and their respective melting points 
determined. Two internal standards, a macaque Class I MHC molecule in 100 
mM Pyridine-HCl buffer pH 5.5 and gamma globulin in 100 mM Imidazole 
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buffer pH 7.0 were used for every run to ensure the RT-PCR machine is in 





3.3.1 Crystal structure of Rop7c1 TCR 
 
In collaboration with the Rob Meijers’ group from European Molecular 
Biology Laboratory Hamburg, we have obtained the crystal structure of the 
Rop7c1 TCR to a resolution of 2.25Å (Fig. 12). The α chain is shown in green 
whilst the β chain is represented in cyan. The Complementary Determining 
Regions (CDRs) are also highlighted. In addition, the introduced cysteines, 
which form the non-native disulphide bridge between the α and β chains, can 
also be seen to be in close proximity with each other, further confirming both 
chains are connected by the non-native disulphide bridge introduced. 
 
3.3.2 Production of supercharged Rop7c1 TCR α and β chains 
 
Together with the crystal structure data of the Rop7c1 TCR, we utilized the 
AvNAPSA program, obtained from David Liu’s group, to identify amino acid 
residues which are solvent exposed i.e. amino acid residues with low 
AvNAPSA values. Solvent exposed residues typically have an AvNAPSA 
value of less than 150 109. Out of these solvent exposed residues, the positively 
charged residues, Arginine (R) and Lysine (K), the negatively charged 
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residues, Aspartic acid (D) and Glutamic acid (E), as well as the polar residues 
Asparagine (N) and Glutamine (Q), were considered for mutations. However, 
if these residues were located at the CDRs of the α and β chains, they were 
unchanged so as not to affect TCR recognition of its cognate pMHC. 
 
 
Figure 12. Crystal structure of Rop7c1 TCR. The α and β chain are shown in green and 
cyan respectively with the introduced cysteines forming the non-native disulphide bridge 
shown in yellow. The CDR regions of each chain: CDR1α (pink), CDR2α (blue), CDR3α 
(orange), CDR1β (magenta), CDR2β (red) and CDR3β (brown) are also indicated. The upper 
left panel shows the crystals generated during screens and the bottom left panel is an example 
of the diffraction data. (Data shared by Dr. Jonathan Rapley and Dr. Rob Meijers) 
 
There were a total of 228 amino acid residues that were solvent exposed 
(AvNAPSA <150) with 92 amino acid residues amenable for mutations. 
Mutating all 92 amino acid residues might be too harsh on the protein and 
thus, we grouped the solvent exposed residues according to their AvNAPSA 
scores in a bid to create a few constructs to investigate the effects 
























α -5 +1 <60 11 8 β -3 +3 
α -16 +6 <80 37 19 β -11 +5 
α -25 +23 <100 81 41 β -25 +9 
α -28 +19 <120 149 66 β -19 +19 
α -32 +26 <140 208 85 β -27 +28 
α -32 +29 <150 228 92 β -30 +32 
 
Table 2. AvNAPSA scores for Rop7c1 TCR. The solvent exposed residues 
of the Rop7c1 TCR were grouped according to their AvNAPSA scores with 
the number of residues amenable for mutation indicated. The final charges of 
the individual α and β chains in each group are also shown. 
 
We selected AvNAPSA cutoff values of <80 and <100 and created constructs 
for Rop7c1α (-16), Rop7c1α (-25), Rop7c1α (+6), Rop7c1α (+23), Rop7c1β (-
11), Rop7c1β (-25), Rop7c1β (+5) and Rop7c1β (+9). We also made sure that 
the mutated residues are surface exposed and away from the CDRs by visual 
inspection of the crystal structure. To create a more positively charged TCR, 
we mutated Q, N, D and E to either a K or R. On the other hand, to create a 
more negatively charged TCR, we mutated Q, N, K and R to either a D or E.  
We then submitted the dimeric TCR to the online protein design server, 
RosettaDesign, and only allowed the selected resiudes to mutate to either K or 




1        10        20            1        10        20    
(-25) MGQQVEQSPASLVLQEGEDAELQCNF (-25) MEAAVTQSPRNKVTVTGGEVTLSC 
(-16) MGQQVQQSPASLVLQEGENAELQCNF (-11) MEAAVTQSPRNKVTVTGGNVTLSC 
(WT)  MGQQVQQSPASLVLQEGENAELQCNF (WT)  MEAAVTQSPRNKVTVTGGNVTLSC 
  -CDR1       40        -CD          -CDR1       40 
(-25) STSLNSMQWFYQRPGGSLVSLFYNPS (-25) EQTNSHNYMYWYRQDTGHGLRLIH 
(-16) STSLNSMQWFYQRPGGSLVSLFYNPS (-11) RQTNSHNYMYWYRQDTGHGLRLIH 
(WT)  STSLNSMQWFYQRPGGSLVSLFYNPS (WT)  RQTNSHNYMYWYRQDTGHGLRLIH 
      R2    60        70                -CDR2-    60        70 
(-25) GTKESGRLTSTTVIDEERSSLHISSS (-25) YSYGAGNLQIGDVPDGYEATRTTQ 
(-16) GTKQSGRLTSTTVIDERRSSLHISSS (-11) YSYGAGNLQIGDVPDGYKATRTTQ 
(WT)  GTKQSGRLTSTTVIKERRSSLHISSS (WT)  YSYGAGNLQIGDVPDGYKATRTTQ 
      80        90 –CDR3--                    80        90   -C 
(-25) QTTDSGTYLCAMGDTNAYKVIFGKGT (-25) EDFFLLLELASPSQTSLYFCASSE 
(-16) QTTDSGTYLCAMGDTNAYKVIFGKGT (-11) EDFFLLLELASPSQTSLYFCASSE 
(WT)  QTTDSGTYLCAMGDTNAYKVIFGKGT (WT)  EDFFLLLELASPSQTSLYFCASSE 
          110       120      129       DR3-    105       115      
(-25) HLHVLPNIEDPEPAVYQLKDPDSDDS (-25) AGDTEVFFGDGTRLTVVEDLDNVT 
(-16) HLHVLPNIEDPEPAVYQLKDPDSDDS (-11) AGDTEVFFGKGTRLTVVEDLDNVT 
(WT)  HLHVLPNIQNPEPAVYQLKDPRSQDS (WT)  AGDTEVFFGKGTRLTVVEDLRNVT 
              140       150            121      130       140 
(-25) TLCLFTDFDSDIEVPDTMESGTFITD (-25) PPEVSLFEPSDAEIANKDKATLVC 
(-16) TLCLFTDFDSQIEVPDTMESGTFITD (-11) PPKVSLFEPSKAEIANKQKATLVC 
(WT)  TLCLFTDFDSQINVPKTMESGTFITD (WT)  PPKVSLFEPSKAEIANKQKATLVC 
        160       170       180             150       160 
(-25) KCVLDMEAMDSKSNGAIAWSEETSFT (-25) LARGFFPDHVELSWWVNGEEVHSG 
(-16) KCVLDMEAMDSKSNGAIAWSNQTSFT (-11) LARGFFPDHVELSWWVNGEEVHSG 
(WT)  KCVLDMKAMDSKSNGAIAWSNQTSFT (WT)  LARGFFPDHVELSWWVNGKEVHSG 
            190                         170       180       190 
(-25) CQDIFEETDATYPSS            (-25) VCTDPQAYKESEYSYALSSRLRVS  
(-16) CQDIFEETNATYPSS            (-11) VCTDPQAYKESEYSYALSSRLRVS 
(WT)  CQDIFKETNATYPSS            (WT)  VCTDPQAYKESNYSYALSSRLRVS 
                                              200       210 
                                 (-25) ATFWHNPDNHFRCQVQFHGLSEED 
                                 (-11) ATFWHNPRNHFRCQVQFHGLSEED 
                                 (WT)  ATFWHNPRNHFRCQVQFHGLSEED  
                                          220       230 
                                 (-25) EWPEGSPKPVTQNISAEAWGRALP 
                              (-11) EWPEGSPKPVTQNISAEAWGRALP 
                                 (WT)  KWPEGSPKPVTQNISAEAWGRALP 
                                       241      250 
                                 (-25) ETGGLNDIFEAQKIEWHE	  
                                 (-11) ETGGLNDIFEAQKIEWHE	  
                                 (WT)  ETGGLNDIFEAQKIEWHE 
 
Figure 13. Positions of mutations for negative supercharging of Rop7c1 TCR. (A) The 
crystal structure of the Rop7c1 TCR is shown with the α chain colored grey and the β chain 
colored black. Mutations to amino acid residues are highlighted in red and magenta. The 
sequence of the α chain is shown below detailing the amino acid residue mutated. Positively 
charged residues, K and R, are shown in blue whilst negatively charged residues, D and E, are 
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shown in red. (B) The crystal structure of the Rop7c1 TCR with the β chain colored grey and 
the mutations highlighted in red and magenta. The sequence of the β chain showing the 
respective mutations to negatively charged residues is shown below.  
 
 
The RosettaDesign program designs novel proteins by selecting for amino 
acids that pack well with the wild-type protein, bury their hydrophobic atoms 
and satisfy the hydrogen bonding potential of polar atoms. Figure 13 and 
Figure 14 shows the sites of mutations, as well as the amino acid residues 
mutated for negative and positive supercharging respectively.  
 
 
1        10        20            1        10        20    
(+6)  MGQQVQQSPASLVLQEGENAELQCNF (+5)  MEAAVTQSPRNKVTVTGGNVTLSC 
(+23) MGQQVRQSPASLVLQEGRKARLQCNF (+9)  MEAAVTQSPRNKVTVTGGRVTLSC 
(WT)  MGQQVQQSPASLVLQEGENAELQCNF (WT)  MEAAVTQSPRNKVTVTGGNVTLSC 
  -CDR1       40        -CD          -CDR1       40 
(+6)  STSLNSMQWFYQRPGGSLVSLFYNPS (+5)  RQTNSHNYMYWYRQDTGHGLRLIH 
(+23) STSLNSMQWFYQRPGGSLVSLFYNPS (+9)  RQTNSHNYMYWYRQDTGHGLRLIH 
(WT)  STSLNSMQWFYQRPGGSLVSLFYNPS (WT)  RQTNSHNYMYWYRQDTGHGLRLIH 
      R2    60        70                -CDR2-    60        70 
(+6)  GTKQSGRLTSTTVIKKRRSSLHISSS (+5)  YSYGAGNLQIGDVPKGYKATRTTQ 
(+23) GTKRSGRLTSTTVIKKRRSSLHISSS (+9)  YSYGAGNLQIGDVPKGYKATRTTQ 
(WT)  GTKQSGRLTSTTVIKERRSSLHISSS (WT)  YSYGAGNLQIGDVPDGYKATRTTQ 
      80        90 –CDR3--                    80        90   -C 
(+6)  QTTDSGTYLCAMGDTNAYKVIFGKGT (+5)  EDFFLLLELASPSQTSLYFCASSE 
(+23) QTTDSGTYLCAMGDTNAYKVIFGKGT (+9)  EDFFLLLKLASPSQTSLYFCASSE 
(WT)  QTTDSGTYLCAMGDTNAYKVIFGKGT (WT)  EDFFLLLELASPSQTSLYFCASSE 
          110       120      129       DR3-    105       115      
(+6)  HLHVLPNIKRPEPAVYQLKDPRSRKS (+5)  AGDTEVFFGKGTRLTVVEDLRNVT 
(+23) HLHVLPNIKRPRPAVYQLKDPRSRKS (+9)  AGDTEVFFGKGTRLTVVEDLRNVT 
(WT)  HLHVLPNIQNPEPAVYQLKDPRSQDS (WT)  AGDTEVFFGKGTRLTVVEDLRNVT 
              140       150            121      130       140 
(+6)  TLCLFTDFDSQIKVPKTMESGTFITD (+5)  PPKVSLFEPSKAEIANKQKATLVC 
(+23) TLCLFTDFDSRIKVPKTMESGTFITD (+9)  PPKVSLFEPSKAEIANKKKATLVC 
(WT)  TLCLFTDFDSQINVPKTMESGTFITD (WT)  PPKVSLFEPSKAEIANKQKATLVC 
        160       170       180             150       160 
(+6)  KCVLDMKAMDSKSNGAIAWSNQTSFT (+5)  LARGFFPDHVELSWWVNGKEVHSG 
(+23) KCVLDMKAMKSKSNGAIAWSRKTSFT (+9)  LARGFFPDHVELSWWVNGKEVHSG 
(WT)  KCVLDMKAMDSKSNGAIAWSNQTSFT (WT)  LARGFFPDHVELSWWVNGKEVHSG 
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            190                         170       180       190 
(+6)  CQDIFKETNATYPSS            (+5)  VCTDPQAYKESKYSYALSSRLRVS  
(+23) CQDIFKKTKATYPSS            (+9)  VCTDPQAYKESKYSYALSSRLRVS 
(WT)  CQDIFKETNATYPSS            (WT)  VCTDPQAYKESNYSYALSSRLRVS 
                                              200       210 
                                 (+5)  ATFWHNPRNHFRCQVQFHGLSRKD 
                                 (+9)  ATFWHNPRNHFRCQVQFHGLSRKD 
                                 (WT)  ATFWHNPRNHFRCQVQFHGLSEED  
                                          220       230 
                                 (+5)  KWPRGSPKPVTQNISAEAWGRALP 
                              (+9)  KWPRGSPKPVTQNISAEAWGRALP 
                                 (WT)  KWPEGSPKPVTQNISAEAWGRALP 
                                       241      250 
                                 (+5)  ETGGLNDIFEAQKIEWHE	  
                                 (+9)  ETGGLNDIFEAQKIEWHE	  
                                 (WT)  ETGGLNDIFEAQKIEWHE	  	  
Figure 14. Positions of mutations for positive supercharging of Rop7c1 TCR. (A) The 
crystal structure of the Rop7c1 TCR is shown with the α chain colored grey and the β chain 
colored black. Mutations to amino acid residues are highlighted in blue and cyan. The 
sequence of the α chain is shown below detailing the amino acid residue mutated. Positively 
charged residues, K and R, are shown in blue whilst negatively charged residues, D and E, are 
shown in red. (B) The crystal structure of the Rop7c1 TCR with the β chain colored grey and 
the mutations highlighted in blue and cyan. The sequence of the β chain showing the 
respective mutations to positively charged residues is shown below.  
 
 
3.3.3 Production and purification of supercharged Rop7c1 TCRs 
 
The supercharged constructs were then cloned into bacterial expression 
vectors and the individual chains produced by bacteria similar to that of the 
Rop7c1 TCR α and β chains via IPTG induction (Fig. 15). All the constructs 
showed strong induction upon IPTG addition with relatively pure protein 
obtained after inclusion body purification. However, Rop7c1β (+9) was the 
most weakly induced amongst the constructs and a much lower amount of 
protein was purified from the inclusion bodies (Fig. 15D).  
 
The Rop7c1α and β chain has a molecular weight of approximately 21.7 kDa 
and 29 kDa respectively. Supercharging both the α and β chains did not 




Figure 15. Expression of individual supercharged TCR chains. SDS-PAGE gels for 
bacteria expressing (A) negatively supercharged Rop7c1α, (B) negatively supercharged 
Rop7c1β, (C) positively supercharged Rop7c1α and (D) positively supercharged Rop7c1β. 
Pre (-) and post (+) IPTG induction were shown with the final protein isolated from inclusion 
bodies (I.B.). Due to their high net charge, Rop7c1α (-25) and Rop7c1α (+23), for example, 
migrated to a position different from their molecular weight of ~22 kDa. 
 
However, for the Rop7c1α (-25) and Rop7c1α (-16) chains, we see that the 
induced protein bands appear at above 25 kDa (Fig. 15A), unlike the wild-
type Rop7c1α which appears below 25 kDa (Fig. 2). Proteins migrate in SDS-
PAGE based on size and charge. Thus, due to the nature of their higher net 
charge, they migrate differently from the wild type α chain. This can also be 
seen where the higher charged Rop7c1α (+23) chain migrates to a position 
around 25 kDa whilst the lower charged Rop7c1α (+6) migrates to a position 
similar to that of the wild type i.e. between 20 kDa and 25 kDa (Fig. 15C). 
The same can also be said for the β chain where we see that Rop7c1β (-25) 
migrates to a position higher than that of the Rop7c1β (-11) chain (Fig. 15B).  
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With the individual supercharged chains produced, we went on to refold the 
TCRs in a manner similar to the production of the wild-type Rop7c1 TCR. We 
first attempted to produce a TCR with a net charge of -13, wild-type Rop7c1α 
with a net charge of (-2) paired with Rop7c1β (-11). After refolding, we used 
size exclusion chromatography to isolate the refolded protein from misfolded 
aggregates (Fig. 16A). We then removed the salt from the buffer containing 
the refolded protein (Fig. 16B), before using anion-exchange chromatography 
to isolate the pure and refolded TCR (Fig. 16C). A single major peak can be 
observed in the anion-exchange chromatogram and we proceeded to confirm 
its identity with SDS-PAGE (Fig. 16D). From the SDS-PAGE gel, we see the 
α chain and the β chain in the presence of DTT (+DTT). However, in the 
absence of DTT (-DTT), we see only a single band corresponding to the 
combined molecular weight of both the α and β chain. This is due to the chains 
being connected by the non-native disulphide bridge, which remains intact 
under non-reducing conditions, introduced into the α and β chains.  
 
In addition, we also tested the biotinylation status of the refolded TCR. From 
the gel, it can be seen that when excess soluble streptavidin is added to the 
refolded Rop7c1α 1β (-11) TCR, the band corresponding to the TCR 
disappeared but several bands above 100kDa appeared. Thus, it can be 
confirmed that all the Rop7c1α 1β (-11) TCRs are biotinylated, coupled with 






Figure 16. Purification of soluble Rop7c1α 1β (-11) TCR. (A) Size exclusion 
chromatography (S200) of Rop7c1α 1β (-11) TCR. The peak corresponding to the refolded 
TCR is indicated by an asterix. (B) The refolded TCR is then buffer-exchanged to remove the 
salt in the original buffer for subsequent purification. (C) Charge separation chromatography 
(Mono Q) of Rop7c1α 1β (-11) TCR. The refolded TCR was eluted with an increasing 
concentration of 20 mM Tris 1 M NaCl pH 8.0 on an anion exchange column after size 
exclusion purification. (D) SDS PAGE gel shows the individual chains under reducing 
(+DTT) conditions and a single disulphide bridge linked α and β chains band under non-
reducing (-DTT) conditions. Soluble refolded TCRs are also shown to be fully biotinylated as 
they bind to soluble streptavidin completely. 
 
We then went on to refold and purify other supercharged TCR clones with 
similar methods. Rop7c1 (-27), wild-type Rop7c1α paired with Rop7c1β (-
25), was purified and fully biotinlyated as well (Fig. 17). In addition, we were 
also able to purify another TCR clone with a net charge of -27, but this was 
done by pairing Rop7c1α (-16) with Rop7c1β (-11) (Fig. 18). Unlike, 
Rop7c1α 1β (-25), the refolded Rop7c1α (-16) 1β (-11) did not appear as the 




Figure 17. Purification of soluble Rop7c1α 1β (-25) TCR. (A) Size exclusion 
chromatography (S200) of Rop7c1α 1β (-25) TCR. The peak corresponding to the refolded 
TCR is indicated by an asterix. (B) The refolded TCR is then buffer-exchanged to remove the 
salt in the original buffer for subsequent purification. (C) Charge separation chromatography 
(Mono Q) of Rop7c1α 1β (-25) TCR. The refolded TCR was eluted with an increasing 
concentration of 20 mM Phosphate 1 M NaCl pH 7.0 on an anion exchange column after size 
exclusion purification. (D) SDS PAGE gel shows the individual chains under reducing 
(+DTT) conditions and a disulphide bridge linked α and β chains band under non-reducing (-
DTT) conditions. Purified refolded TCRs are also shown to be fully biotinylated as they bind 
to soluble streptavidin completely. 
 
 
Thus, although both TCR clones have a net charge of -27, Rop7c1α (-16) 1β (-
11) appeared to refold to a smaller yield, hinting that mutations in the α chain 
might have reduced its stability and contributed to its overall reduced yield. 
In addition, the refolded Rop7c1α 1β (-11) TCR clone eluted as the major 
product during the anion-exchange chromatography (Fig. 16C), further 





Figure 18. Purification of soluble Rop7c1α (-16) 1β (-11) TCR. (A) Size exclusion 
chromatography (S200) of Rop7c1α (-16) 1β (-11) TCR. The peak corresponding to the 
refolded TCR is indicated by an asterix. (B) The refolded TCR is then buffer-exchanged to 
remove the salt in the original buffer for subsequent purification. (C) Charge separation 
chromatography (Mono Q) of Rop7c1α (-16) 1β (-11) TCR. The refolded TCR was eluted 
with an increasing concentration of 20 mM Phosphate 1 M NaCl pH 7.0 on an anion exchange 
column after size exclusion purification. (D) SDS PAGE gel shows the individual chains 
under reducing (+DTT) conditions and a disulphide bridge linked α and β chains band under 
non-reducing (-DTT) conditions. Soluble refolded TCRs are also shown to be fully 
biotinylated as they bind to streptavidin completely. 
 
Other than negatively supercharging the Rop7c1 TCR, we tried to positively 
supercharge the Rop7c1 TCR as well. We were able to purify the Rop7c1α 1β 
(+5) TCR clone with a net charge of +3 (Fig. 19). Although a pure product 
was obtained, this TCR clone refolded with the least yield compared to the 
other supercharged clones. 
 
We also tried to refold and purify other positively supercharged TCR clones 
but were not successful as the α and β chains seemed to misfold or did not 




Figure 19. Purification of soluble Rop7c1α 1β (+5) TCR. (A) Size exclusion 
chromatography (S200) of Rop7c1α 1β (+5) TCR. The peak corresponding to the refolded 
TCR is indicated by an asterix. (B) The refolded TCR is then buffer-exchanged to remove the 
salt in the original buffer for subsequent purification. (C) Charge separation chromatography 
of Rop7c1α 1β (+5) TCR. The refolded TCR was eluted with an increasing concentration of 
20 mM Phosphate 1 M NaCl pH 7.0 on a cation exchange column (Mono S) after size 
exclusion purification. (D) SDS PAGE gel shows the individual chains under reducing 
(+DTT) conditions and a disulphide bridge linked α and β chains band under non-reducing (-
DTT) conditions. All of the refolded TCRs are shown to be biotinylated as indicated by the 
addition of soluble streptavidin. 
 
 
Figure 20A shows the size exclusion chromatogram for the Rop7c1 TCR. The 
first peak corresponds to the soluble aggregates whilst the second peak, 
indicated by an asterix, represents the refolded TCR. The Rop7c1α (+6) 1β 
(+9) TCR was also subjected to size exclusion chromatography after refolding 
but instead of observing a single peak at around 80 ml similar to that of the 
Rop7c1 TCR, we see two prominent peaks, around 60 ml and around 90 ml 
(Fig. 20B). The peak around 60 ml corresponds to proteins with a molecular 
weight of approximately 158 kDa whilst the peak around 90 ml corresponds to 
proteins with a molecular weight of about 25 kDa. Thus, it seems that for the 
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Rop7c1α (+6) 1β (+9) TCR clone, the α and β chains are either not binding to 
each other or have misfolded and aggregated. A similar chromatogram is also 
seen for another positively supercharged TCR clone, Rop7c1α (+23) 1β (+5), 
where the major peak occurs at 90 ml (Fig. 20C).   
 
 
Figure 20. Size exclusion chromatograms of various TCRs. (A) Size exclusion 
chromatography (S200) of Rop7c1 TCR. The peak corresponding to the refolded TCR is 
indicated by an asterix and elutes at approximately 80ml. (B) Size exclusion chromatography 
of Rop7c1α (+6) 1β (+9) after refolding. Two peaks, one around 60 ml and another around 90 
ml, corresponding to approximately 158 kDa and 25 kDa respectively were observed instead 
of the expected peak at 80ml. (C) Size exclusion chromatography of Rop7c1α (+23) 1β (+5) 
after refolding shows a major peak at around 90ml, indicating that the α and β chain most 
probably did not bind to each other. 
 
We also tested several other combinations of supercharged α and β chains but 
a pure and correctly refolded TCR could not be isolated from these 
combinations (Table 3). From the various refolds done, two points can be 
observed. First, positively supercharged α and β chains do not refold into a 
TCR which can be purified. This may indicate that increasing the positive 
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charges of the α and β chains may be detrimental to them. Second, of the 
successfully refolded supercharged TCRs, only one TCR clone, Rop7c1α (-
16) 1β (-11), contains a supercharged α chain. Thus, it seems that the α chain 
may not be amenable to mutations.  
 
Table 3 
TCR chain Charges 
α -2 -2 -2 -2 -16 -25 +6 +23 
β -11 -25 +5 +9 -4 -4 -4 -4 
Yield / L 
refold (mg) ~0.36  ~0.2  ~0.1  X X X X X 
 
TCR chain Charges (α chain –ve) 
α -16 -16 -16 -16 -25 -25 -25 -25 
β -11 -25 +5 +9 -11 -25 +5 +9 
Yield / L 
refold (mg) ~0.2  N.D. X N.D. X X X N.D. 
 
TCR chain Charges (α chain +ve) 
α +6 +6 +6 +6 +23 +23 +23 +23 
β -11 -25 +5 +9 -11 -25 +5 +9 
Yield / L 
refold (mg) X X X X X X X X 
 
Table 3. Attempted refolds of supercharged TCRs. The top row indicates refolding of 
supercharged TCRs with only either the α or the β chains mutated. The middle row indicates 
all combinations with negatively supercharged α chain whilst the last row indicates all 
combination with the positively supercharged α chain. The yield of the TCRs per 1 Litre 
refold are indcated for the successful clones. X represents failure to refold and purify the TCR 
whilst N.D. refers to combinations not attempted. 
 
Although the mutations were designed to be on the surfaces of the α and β 
chains so as not to affect the folding of the individual chains, the large amount 
of charges present on the surfaces of the α and β chains may disrupt the inter-
chain or subunit interaction. To check if this may be the case, we looked at the 
surface electrostatics of the Rop7c1 TCR (Fig. 21). From the figure, we see 
clusters of positively (blue) and negatively (red) charged amino acid residues 
on the surface of the TCR. In addition, as we look at the binding interface 
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between the α and the β chain, we see that the charged amino acid residues 
seems to occupy the top and the bottom of the molecule at the interface. The 
constant region of the α chain at the binding interface appears to be negatively 
charged (top), whilst its variable region is positively charged (bottom). Of note 
is the β chain has opposite charges on these regions at the binding interface as 
compared to the α chain. This complementarity in charges may aid in the 
pairing of the α and β chain.  
 
 
Figure 21. Surface charge distribution of the Rop7c1 TCR. The structure on the left 
indicates the surface charges on the refolded Rop7c1 TCR with clusters of blue representing 
positively charged regions and clusters of red representing negatively charged regions. The 
structures on the right show the binding interface (pointing out of page) between the α and β 
chains. 
 
We then looked at surface electrostatics of the various supercharged clones to 
see if there could be electrostatic repulsion at the binding interface between 
the charged clones (Fig. 22). We observe that for the positively supercharged 
β chain and the negatively supercharged α and β chains, the constant and 
variable regions at the binding interface remain largely the same charge as the 
wild type (Fig. 21). However, for the positively supercharged α chains, their 
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constant region at the binding interface appears to be much less negatively 
charged and even slightly positively charged for the Rop7c1α (+23). Although 
it might be tempting to propose that this would hinder the pairing between the 
positively supercharged α chains with the β chains, thus explaining the failure 
to obtain correctly refolded positively supercharged TCRs, there is no 
conclusive evidence since the negatively supercharged α and β chains, 
Rop7c1α (-16) 1β (-25) and Rop7c1α (-25) 1β (-25) for example, have failed 




Figure 22. Surface charge distribution of supercharged chains. Electrostatic charges on 
the surfaces of the (A) negatively supercharged α chain, (B) negatively supercharged β chain, 
(C) positively supercharged α chain and (D) positively supercharged β chain are shown. All 





3.3.4 Functional avidity and specificity of supercharged TCRs 
 
Next, we went on to investigate if the refolded supercharged TCR clones can 
still specifically recognize the Ld Rop7 MHC. We immobilized saturating 
amounts of TCRs on streptavidin coated flow cytometry beads and used 
titrating amounts of Ld Rop7 MHC – PE to test for functional avidity as well 
as specificity (Fig. 23). Although all supercharged clones are specific for the 
Ld Rop7 MHC, it can be clearly seen that they bind with different avidity.  
Rop7c1α 1β (-11) and Rop7c1α 1β (+5) exhibited almost no difference in 
terms of binding avidity as compared to Rop7c1 TCR (Fig. 23F). However, as 
the net charge of the TCR increases, the binding avidity to the Ld Rop7 MHC 
decreases. A possible explanation for this could be the repulsion between the 
TCR and the pMHC due to electrostatic charges. The Ld Rop7 MHC has an 
estimated P.I. (isoelectric point) of approximately 5.9. Thus, it is negatively 
charged in the buffer used for the staining experiment. Although Rop7c1α 1β 
(-11) binds with similar avidity as the wild type TCR, Rop7c1α 1β (-25), with 
a higher negative net charge, binds with a lower avidity. In addition, the 
Rop7c1 (+5) TCR binds with a slightly higher avidity as compared to the wild 
type TCR (Fig. 23F). It also binds to the control Ld Gra4 MHC with a slightly 
higher avidity as well (Fig. 23E). Thus, it would seem that although the 
charges on the surface of the TCR do not affect its specificity, they affect its 
binding to the cognate ligand, possibly due to electrostatic charges 
interactions. In contrast, the Rop7c1α (-16) 1β (-11), wih the same negative 
net charge as Rop7c1α 1β (-25), binds with an even lower avidity than the 
Rop7c1α 1β (-25). This would imply that changes in the α chain in the TCR 
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can also drastically decrease the binding avidity of the TCR, possibly due to a 
decrease in stability of the complex.  
 
 
Figure 23. Functional avidity of the supercharged TCRs. Saturating amounts of  (A) Wild-
type Rop7c1, (B) Rop7c1α 1β (-11), (C) Rop7c1α 1β (-25), (D) Rop7c1α (-16) 1β (-11) and 
(E) Rop7c1α 1β (+5) were bound to streptavidin coated beads and incubated with titrating 
amounts of Ld Rop7 MHC conjugated with PE. (F) The staining intensities of the of the wild-
type and supercharged clones are plotted against the amount of pMHC titrated for comparison.                                                                 
 
 
Next, we tested if the TCR tetramers could also bind to murine cells. We first 
peptide-pulsed RAW cells, a murine macrophage cell line which expresses the 
murine MHC Class I molecule, Ld, with either a non-specific peptide, Gra4, or 
 86	  
the cognate ligand, the Rop7 peptide. We then stained them with 2 µM of 
TCR tetramers. A titration of TCR tetramers staining was done previously and 
this concentration of TCR tetramers was chosen as higher concentrations did 
not lead to a significant increase in binding (not shown). Figure 24A shows 
the flow cytometry plot after staining. CD4 (red), a marker for CD4 T cells, 
was used as a negative control, whilst F4/80 (blue), a pan macrophage marker, 
was used as a positive control. When the cells were pulsed with the control 
peptide Gra4 and stained with the Rop7c1 tetramers (orange), we see an 
increase in fluorescence intensity as compared to the CD4 stain. This may 
imply that the TCR tetramers are sticking to the cells non-specifically as we 
have already proved the specificity of the TCR tetramers previously with the 
beads assay (Fig. 23). This is further confirmed when the same amount of 
fluorescence is detected when unpulsed cells were stained with the TCR 
tetramers (green). However, when the cells are pulsed with the cognate 
peptide and stained with TCR tetramers, we noticed an increase in 
fluorescence intensity, albeit a small one (cyan). Thus, although the Rop7c1 
TCR tetramers are sticking non-specifically to the cells, it is specific for the 
Rop7 peptide antigen. Similarly, we see the same stainings for Rop7c1α 1β (-
11) and Rop7c1α 1β (+5) (Fig. 24B and 24E). This is expected as we have 
previously shown that these three TCR tetramers possess similar binding 
avidity. On the other hand, the Rop7c1α 1β (-25) tetramer bound to the Rop7 
pulsed cells to a smaller extent (Fig. 24C) whilst the Rop7c1α (-16) 1β (-11) 
TCR tetramer did not bind at all. This is in agreement with our previous 
binding studies showing that the Rop7c1α 1β (-25) tetramer has a weaker 
binding avidity and the Rop7c1α (-16) 1β (-11) TCR binds the weakest to its 
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cognate ligand (Fig. 23). We then plotted the change in fluorescence intensity 
obtained from tetramer staining between the Rop7 pulsed cells and the control 
Gra4 pulsed cells with a bar graph (Fig. 24F) From the bar graph, it can easily 
be seen that the binding of the TCR tetramers to the RAW cells is dependent 
on its binding avidity. 
 
 Figure 24. Binding of supercharged TCR tetramers to RAW 264 cells. RAW cells were 
pulsed with either the control Gra4 peptide or the cognate ligand Rop7 peptide and stained 
wth (A) Rop7c1 (B) Rop7c1α 1β (-11) (C) Rop7c1α 1β (-25), (D) Rop7c1α (-16) 1β (-11) and 
(E) Rop7c1α 1β (+5) tetramers. CD4 and F4/80 act as negative and positive markers for the 
RAW cells. (F) The fold change in fluorescence intensity between binding to the Rop7 pulsed 
cells and the Gra4 pulsed cells for each TCR tetramer clone is shown. A fold change of 1, 
indicated by blue dotted line, would indicate no specific binding of the TCR tetramer to the 
Rop7 pMHC. The fold change in fluorescence intensity is in agreement with the binding 
avidity of each clone.  
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In addition, we also observed that a higher level of staining for the Rop7c1 
(+5) TCR tetramers for the unpulsed, control peptide as well as the cognate 
ligand as compared to the other clones. Heparan sulphate proteoglycans are 
found on the plasma membrane of mammalian cells and are highly negatively 
charged 175. Thus, the Rop7c1 (+5) TCR tetramers may be attracted non-
specifically to the cell membrane of the cells, thereby explaining the increase 
in staining seen. 
 
 
3.3.5 Stabilities of supercharged Rop7c1 TCRs 
 
With the successful purification of various supercharged TCR clones, we 
proceeded to assess their thermostabilities in various different buffer 
conditions. To do this, we employed a method known as Differential Scanning 
Fluorimetry (DSF) with a dye (SyPro Orange) that becomes highly fluorescent 
under non-polar conditions 176. In principle, most proteins retain their native 
conformation at physiological or room temperature, burying their hydrophobic 
cores and exposing the hydrophilic residues. Thus, a basic level of 
fluorescence intensity of the dye is observed upon excitation (Fig. 25). 
However, as the temperature increases, the protein starts to unfold, exposing 
hydrophobic patches. As the dye binds to these non-polar regions, it fluoresces 
brightly, leading to a sharp increase in the fluorescence intensity detected. As 
the temperature further increases, the protein becomes fully denatured and 
aggregates. This reduces the number of hydrophobic patches exposed leading 
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to a decrease in the intensity of the dye observed (Fig. 25). A melt curve for 
the protein can thus be generated.  
 
The Gibbs free energy of unfolding for a protein is related to its stability and is 
dependent on temperature 177. The melting temperature (Tm) of a protein can 
be considered as the temperature where there are equal concentrations of 
folded and unfolded proteins i.e. the Gibbs free energy is zero and at 
equilibrium. This corresponds to the point of inflexion on the sigmoidal curve 
between the highest and the lowest level of fluorescence (Fig. 25). 
 
Figure 25. Differential Scanning Fluorimetry. A protein (blue oval) maintains its native 
conformation at room and physiological temperatures, exposing few hydrophobic patches. 
SyPro Orange (orange spheres) gives a baseline of fluorescence intemsity with little non-polar 
regions for it to bind to. As the temperature increases, the protein starts to unfold at a rapid 
rate, exposing more and more hydrophobic regions. This results in rapid binding of the dye to 
non-polar regions on the unfolded protein, indicated by a sharp rise in fluorescence intensity. 
As the temperature continues to increase, the protein becomes fully denatured and begins to 
aggregate. This reduces the number of hydrophobic patches exposed leading to a decrease in 
the fluorescence intensity of SyPro Orange. A melt curve for the protein is thus generated. 
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The simplest way to calculate the Tm value for a protein would be to obtain the 
maxima of the first derivative of the melt curve 176. We proceeded to first 
determine the Tm of the Rop7c1 TCR in a range of conditions so that a 
baseline can be set for comparison. A range of conditions (Table 4) was also 
selected to see if changes in stability were universal or increase in charges 




- : Control I 
+ : Control II 
1 : Na Acetate pH 5.0 
2 : Pyridine HCl pH 5.5 
3 : Na Cacodylate PH 6.0 
4 : MES pH 6.0 
5 : Imidazole pH 7.0 
6 : PIPES pH 7.0 
7 : MOPS pH 7.2 
8 : HEPES pH 7.5 
9 : Tricine pH 8.0 
10 : Tris pH 8.1 
11 : Bicine pH 8.3 
12 : Glycine pH 9.0 
13 : CHES pH 9.5 
14 : Ethanolamine pH 9.5 
15 : CAPS pH 10.0 
16 : HEPES 50 mM NaCl 
17 : HEPES 150 mM NaCl 
18 : HEPES 500 mM NaCl 
19 : HEPES 150 mM NaCl 5% glycerol 
20 : HEPES 150 mM NaCl 10% glycerol 
21 : HEPES 500 mM NaCl 5% glycerol 
 
Table 4. Buffer conditions for stability assays. Control I (-) refers to a 
macaque Class I MHC molecule in 100 mM Pyridine-HCl buffer pH 5.5 
whilst Control II (+) is gamma globulin in 100 mM Imidazole buffer pH 7.0. 





Figure 26A shows the melt curves generated for Rop7c1 TCR under the first 
five different conditions as indicated in Table 4. As expected, we see that a 
basal fluorescence intensity of SyPro Orange is observed for the TCR across 
the conditions. However, as the temperature increases above physiological 
temperatures, the TCR unfolds, leading to a huge increase in the fluorescence 
intensity of SyPro Orange. A decrease in the fluorescence of SyPro Orange is 
then seen as the TCR becomes fully denatured at higher temperatures. We 
probed the changes in the fluorescence intensity of the dye as well in buffer 
alone without protein to confirm that temperature changes do not affect the 
fluorescence intensity of SyPro Orange. We then plotted the first derivative of 
the melt curves so as to determine the Tm of the Rop7c1 TCR under the 
various conditions (Fig. 26B). Control I (Macaque Class I MHC in Pyridine-
HCl pH 5.5) and Control II (Gamma globulin in Imidazole pH 7) were 
included as a reference for every experiment. Figures 26C and 26E show melt 
curves for the Rop7c1 TCR for the remaining conditions whilst Figures 26D 
and 26F show their derivative curves respectively. The Tm of the Rop7c1 TCR 
at various conditions i.e. the maxima of the derivative curves at the respective 
conditions, were then plotted in the form of a bar graph for easy comparison 
(Fig. 26G). From the bar graphs, we can see that the melting temperatures of 
the Rop7c1 TCR are similar across most conditions except harsh conditions 
such as Na Acetate pH 5 (1), Pyridine HCl pH 5.5 (2), MES pH 6 (4) and 
CAPS pH 10 (15).  
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With the necessary controls set up, we went on to detemine the Tm for the 
various charged clones, Rop7c1α 1β (-11) (Fig. 27), Rop7c1α 1β (-25) (Fig. 
28), Rop7c1α (-16) 1β (-11) (Fig. 29) and Rop7c1α 1β (+5) (Fig. 30).  
 
Figure 26. Stability assay for Rop7c1 TCR. (A) Melt curves generated for first set of 
conditions for Rop7c1 TCR. Controls I and II were included to act as internal standards for 
consistency across different experiments. (B) The derivative of the melt curves in A. (C) Melt 
curves generated for the second set of conditions. (D) The derivative of the melt curves in C. 
(E) Melt curves generated for the third set of conditions. (F) The derivative of the melt curves 
in E. (G) Melting temperature (Tm) for the Rop7c1 TCR under various conditions. The 




Figure 27. Stability assay for Rop7c1α 1β (-11) TCR. (A) Melt curves generated for first set 
of conditions for Rop7c1α 1β (-11) TCR. Controls I and II were included to act as internal 
standards for consistency across different experiments. (B) The derivative of the melt curves 
in A. (C) Melt curves generated for the second set of conditions. (D) The derivative of the 
melt curves in C. (E) Melt curves generated for the third set of conditions. (F) The derivative 
of the melt curves in E. (G) Tm for the Rop7c1α 1β (-11) TCR under various conditions. The 




Figure 28. Stability assay for Rop7c1α 1β (-25) TCR. (A) Melt curves generated for first set 
of conditions for Rop7c1α 1β (-25) TCR. Controls I and II were included to act as internal 
standards for consistency across different experiments. (B) The derivative of the melt curves 
in A. (C) Melt curves generated for the second set of conditions. (D) The derivative of the 
melt curves in C. (E) Melt curves generated for the third set of conditions. (F) The derivative 
of the melt curves in E. (G) Tm for the Rop7c1α 1β (-25) TCR under various conditions. The 
numbers corresponding to the conditions tested are indicated in Table 4. 
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Figure 29. Stability assay for Rop7c1α (-16) 1β (-11) TCR. (A) Melt curves generated for 
first set of conditions for Rop7c1 TCR. Controls I and II were included to act as internal 
standards for consistency across different experiments. (B) The derivative of the melt curves 
in A. (C) Melt curves generated for the second set of conditions. (D) The derivative of the 
melt curves in C. (E) Melt curves generated for the third set of conditions. (F) The derivative 
of the melt curves in E. (G) Tm for the Rop7c1α (-16) 1β (-11) TCR under various conditions. 






Figure 30. Stability assay for Rop7c1α 1β (+5) TCR. (A) Melt curves generated for first set 
of conditions for Rop7c1α 1β (+5) TCR. Controls I and II were included to act as internal 
standards for consistency across different experiments. (B) The derivative of the melt curves 
in A. (C) Melt curves generated for the second set of conditions. (D) The derivative of the 
melt curves in C. (E) Melt curves generated for the third set of conditions. (F) The derivative 
of the melt curves in E. (G) Tm for the Rop7c1α 1β (+5) TCR under various conditions. The 





Similarly, for the Rop7c1α 1β (-11) TCR, Rop7c1α 1β (-25) and the Rop7c1α 
1β (+5) TCR, the Tm remains approximately the same across the conditions 
except for more extreme conditions such as 1, 2, 4, 13 and 15. On the 
contrary, the Tm for the Rop7c1α (-16) 1β (-11) TCR do not vary much across 
the different conditions assayed. Although it may seem that this TCR clone 
might be more stable, its Tms across the conditions appear lower than all the 
other TCR clones. To have a better comparison, the Tms of the different TCR 
clones at the various buffer conditions were plotted together (Fig. 31).  
 
 
Figure 31. Comparison of the Tms of the various TCR clones. The Tms of the Rop7c1 and 
Rop7c1α 1β (-11) TCRs are similar across the range of conditions assayed. As the net charge 
increases, the Tms across the various conditions decreased as shown for the Rop7c1α 1β (-25) 
and Rop7c1α (-16) 1β (-11) TCRs. Although the positively charged Rop7c1 (+5) TCR possess 
similar binding avidity to the wild-type TCR, it is less stable as compared to the Rop7c1 and 
Rop7c1α 1β (-11) TCR. 
 
  
We see that apart from Rop7c1α 1β (-11) TCR, the other supercharged clones 
have lower thermostability in overall as compared to the wild-type TCR. This 
may explain the lower binding avidity observed for the Rop7c1α 1β (-25) TCR 
and the Rop7c1α (-16) 1β (-11) TCR. Although the Rop7c1α 1β (+5) TCR 
 98	  
possess similar binding avidity to the wild-type as well as the Rop7c1α 1β (-
11) TCR (Fig. 23), it is less stable than the latter TCR clone. This may imply 
that introducing positive charges to the TCR chains may be detrimental to 
their stabilities. In addition, other than looking at thermostabilities of the 
charged clones, another way to assess stabilities of the charged TCRs could be 
their resistance to aggregation. To this end, we also tried heating the TCRs 
before cooling them on ice to see if they are more resistant to aggregation, or 
as David Liu’s group observed for the charged GFP, reverse aggregation. 
However, our preliminary studies show all TCRs aggrgegating after heat 
application and none were able to refold back after cooling (not shown). Thus, 






The group of David Liu has shown that by increasing the net surface charge of 
GFP, they could make it more resistant to aggregation and even restore its 
function after thermal denaturation 109. The design of the supercharged GFP 
was done using a program known as AvNAPSA, determining amino acid 
residues that are surface exposed and mutating them to charged residues. 
Moving on, they managed to utilize the supercharged GFP as a vehicle to 
deliver siRNA and protein into mammalian cells 121,122. The groups of Brian 
Kuhlman and Andrew Ellington then went on to show that by increasing the 
charges on a single chain antibody (ScFv), they could also increase its 
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resistance to aggregation at high temperatures 108. In addition, some of the 
supercharged clones show an increase in binding affinity too. However, they 
chose to employ a different approach as the group of David Liu, utilizing a 
molecular modeling program, Rosetta, instead to select the amino aicd 
residues to mutate to achieve the increase in charges. 
 
With successes seen in these proteins, we went on to supercharge the Rop7c1 
TCR and investigated if their stabilities were improved as well. We have 
managed to refold and successfully purified four supercharged clones namely, 
Rop7c1α 1β (-11), Rop7c1α 1β (-25), Rop7c1α (-16) 1β (-11) and Rop7c1α 1β 
(+5). Before looking at their stabilities, we first ascertained if there were any 
changes in their specificities and binding affinities. From Figure 23, we can 
see that the supercharged TCR clones retained their specificities to the Ld 
Rop7 MHC. We also observe that the binding avidities of the Rop7c1α 1β (-
11) TCR and the Rop7c1α 1β (+5) are very much similar to the wild-type 
TCR. However, despite leaving the CDR regions unchanged, we noticed a 
decrease in binding avidity as the Rop7c1 TCR becomes more highly charged, 
as seen in the Rop7c1α 1β (-25) and Rop7c1α (-16) 1β (-11) clone.  
 
One possible reason could be the net charge of the TCR and the pMHC. The 
Ld Rop7 MHC is expected to be negatively charged based on its estimated P.I. 
and thus, the highly negatively charged TCRs, Rop7c1α 1β (-25) and Rop7c1α 
(-16) 1β (-11), might not be able to bind as well to the MHC due to like 
charges repulsion. Similarly, in the work of Miklos et. al., they have observed 
only strong binding with a single clone of negatively supercharged antibody, 
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bearing a net charge of -8.5, specific for the bacteria MS2 coat protein 108. 
Moreover, antibody clones with higher negative charges bound weaker to their 
cognate ligands with highly negatively ones eventually failing to bind at all. 
We obtained the amino acid sequence of the MS2 coat protein (PDB ID: 
1MSC) 178 which the antibody is specific for and found that it is also 
negatively charged at the pH of the binding experiments carried out. Thus, 
surface charges may play a part in binding between the TCR and MHC but 
does not affect the specificity of the TCR. Further evidence can be seen from 
the Rop7c1α 1β (+5) TCR where there seems to be a slight increase in the 
binding avidity to the MHC as compared to the wild-type TCR (Fig. 23). 
However, this increase in binding avidity is not specific as we see the staining 
for the negative peptide, Ld Gra4 MHC, for this TCR clone is also slightly 
higher as compared to the wild type TCR (Fig. 23A and E).  
 
We also tested whether the TCR tetramers could bind to cells expressing the 
Rop7 peptide (Fig. 24). Although some non-specific binding was observed, 
specificity was still retained as we see an increase in fluorescence intensity 
when RAW cells were pulsed with the Rop7 peptide. However, the increase in 
fluorescence intensity was very small, indicating that only a small amount of 
TCR tetramers bound to the Rop7 presenting MHC on the cells. This is not 
unexpected as Laugel et. al. saw a similar small increase in fluorescence when 
they stained Tax peptide pulsed B cells with soluble TCR tetramers specific 
for the peptide 28. In addition, Low et. al. have also shown that the binding of 
soluble TCR tetramers to cell surfaces is highly dependent on the surface 
density of the presented antigen 179. Peptide pulsing involves incubating cells 
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with a large amount of peptide of interest and relies on the displacement of the 
original peptide with the peptide of interest, purely by differences in quantity. 
However, if the original peptide stabilizes the MHC molecule better or binds 
tightly to the binding groove, very low amounts of MHC on the surface of the 
cell will be able to exchange and present the peptide of interest. This would 
explain the low amounts of TCR tetramers binding to the cell surface.     
 
Other than the net charges of proteins, the number of mutations made to the 
TCR may also affect the binding avidity of the protein. The Rop7c1α 1β (-25) 
has the same net charge, -27, as Rop7c1α (-16) 1β (-11). However, Rop7c1α (-
16) 1β (-11) binds with a lower binding avidity as compared to Rop7c1α 1β (-
25) TCR. A total of twelve mutations were carried out on the β chain for 
Rop7c1α 1β (-11) whilst nine mutations on the α chain and four mutations on 
the β chain were carried out on Rop7c1α (-16) 1β (-11). Although there were 
fewer mutations on the β chain, there were significantly more mutations on the 
α chain for Rop7c1α (-16) 1β (-11). The refolding yield for Rop7c1α (-16) 1β 
(-11) is also lower than Rop7c1α 1β (-11) (Table 3), further indicating that the 
mutations to the α chain may be detrimental to the TCR as a whole. In 
addition, all mutated α chains, other than Rop7c1α (-16) 1β (-11), failed to 
refold to a stable product, demonstrating the importance of the α chain in the 
TCR heterodimer. 
 
Next, we compared the stabilities of the supercharged TCRs with the wild type 
TCR. We observe that the Tm of the Rop7c1α 1β (-11) is very much similar to 
the wild type TCR. However, the Rop7c1α 1β (+5), Rop7c1α 1β (-25) and 
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Rop7c1α (-16) 1β (-11) have lower Tms in general across the range of 
conditions tested (Fig. 30). Thus, increasing the net charge of the 
heterodimeric Rop7c1 TCR reduces its thermostability instead of increasing it.  
Currently, there are two methods of supercharging proteins, AvNAPSA and 
Rosetta modeling, both of which selects dissimilar mutations and pros and 
cons exist for both methods 180. As mentioned above, the AvNAPSA method 
has been successfully applied by David Liu’s group to create supercharged 
proteins that are more stable than the wild-type. It selects residues which are 
the most surface exposed i.e. make the least interactions with surrounding 
atoms, so as to minimize the effects of the mutations. In addition, mutations 
are targeted at flexible polar amino acid residues (DERKNQ) to reduce the 
introduction of large structural changes to the molecule. However, some 
drawbacks of the approach exist. First, solvent exposed residues can form 
stabilizing contacts on protein surface. A study on the contribution of salt 
bridges formed by surface residues to the stability of ubiquitin has shown that 
surface salt bridges can help to stabilize a protein 181. Thus, changing the 
surface exposed charged residues may be destabilizing to the TCR. Second, 
AvNAPSA disallows the mutation of surface hydrophobic residues, which 
may be destabilizing to the protein. Last, β-sheet structures have been 
implicated in the aggregation of proteins 182 but AvNAPSA disallows the 
mutation of residues with high β-sheet propensity (IVTFY) 183. 
 
On the other hand, the Rosetta computational modeling software selects amino 
acid residues and the charged type to mutate to based on computed energies 
184. It takes into considerations factors such as hydrogen bonding, electrostatic 
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interactions, side-chain rotamer probability and the native-like abundance of 
each amino acid type 185. Thus, using Rosetta to supercharge proteins can 
preserve the native structure of the protein. However, with an expanded choice 
of residues for mutations, the Rosetta approach may also introduce 
destabilizing interactions, especially with partially buried hydrophobic 
residues.   
 
Recently, Der et. al. compared both approaches to supercharge proteins 180. As 
compared to the Rosetta approach, AvNAPSA required fewer mutations to 
achieve the target net charge, minimizing the pertubations made to the native 
structure. However, the Rosetta approach can mutate hydrophobic residues 
which are exposed to reduce the propensity of the protein to aggregate during 
partial unfolding. The two approaches were also aptly summarized and they 
concluded that both approaches have their merits and failures and recommend 
a combination of both, coupled with testing of various clones to identify 
successful ones. They also found that clones with more than 20 mutations had 
decreased expression yield and stability. This is also similar to our 
observations where the very highly charged Rop7c1 TCR clones failed to 
refold. In addition, we also observed lower expression yield for positively 
charged proteins (Fig. 23), a problem not faced by them and probably protein-
specific.  
 
Thus, moving on, we can compare the mutations recommended by the Rosetta 
approach with those from the AvNAPSA and test if indeed the supercharged 
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clones generated from the Rosetta approach have better stabilities than the 
wild-type, which the AvNAPSA method has failed to produce. 
 
Next, several studies have pointed out that by optimizing charge-charge 
interactions between well-exposed charged groups, significant protein 
stabilization can be achieved 186-188. These interactions are long range and can 
even occur if the residues are located far apart. Although they are minor 
contributions as compared to stabilizing forces such as the hydrophobic effect, 
they become important as the unfolding energy is small due to the almost 
complete cancellation of the strongly stabilizing forces, such as hydrogen 
bonding and hydrophobic effect 189. Focusing solely on the increase of the net 
charge of a protein may thus be too general or simple a method to improve the 
stability of a protein. Strickler et. al. have shown that surface charge-charge 
interactions are important for protein stability and by optimizing these charge-
charge interactions, protein stability can be enhanced as well 190. Several 
studies on different proteins have also indicated the importance of electrostatic 
interactions to the stability of the protein, further supporting the notion that 
vastly changing the surface charge of a protein may be detrimental to its 
stability 188,191. 
 
Thus, additional studies into how each mutated charged residue are affecting 
electrostatic interactions between surface residues can further increase the 
success of creating stable supercharged clones. One way to do this would be to 
study the changes in Gibbs free energy to ascertain if the mutated residues 








CD8+ T cells, also known as Cytotoxic T Lymphocytes (CTLs), are important 
in our combat against several pathogens. They recognize antigenic peptides 
from pathogens which are presented by the host Class I MHC molecules on 
the surface of infected cells. These cells play a huge role in resolving several 
viral diseases such as those caused by EBV 193, the Influenza virus 96, 
Lymphocytic Choriomeningitis Virus (LCMV) 194 and many others. CD8+ 
CTLs are also important in diseases by parasites. The severity of infection by 
the obligate parasite, Toxoplasma gondii, has also been shown to be tightly 
regulated by CD8+ T cells and their production of IFN-γ 126. Although all T 
lymphocytes can undergo cytokine-driven phenotypic changes via bystander 
activation, only T cells which recognize the antigenic peptide presented by the 
infected cells undergo several rounds of proliferation and generate a large 
number of CTL effector progeny 195.  
 
Thus, how T cells recognize the antigenic peptide from pathogens is crucial to 
understand immunity against them. Each T cell clone possesses a unique TCR 
which can recognize pMHCs. As all nucleated cells present class I MHC 
molecules with self-peptide, T cells and their TCRs undergo selection in the 
thymus before entering the periphery so as to prevent autoimmunity i.e. T 
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cells recognizing host cells presenting MHC with self-peptide. In the thymus, 
only T cells expressing TCRs which can bind to host MHC presenting self-
peptide weakly (positive selection) can enter into the periphery as naïve T 
cells. T cells expressing TCRs which bind strongly to self-peptide MHC are 
removed during negative selection. Both forms of selection ensure that T cells 
which enter the periphery can recognize antigenic peptide presented by host 
MHC but wil not be activated by those presenting self-peptide. TCRs studied 
to date have been shown to bind with rather low affinities to their cognate 
pMHC ligands (KD ~ 1µM-100µM) 3 and this is consistent with the selection 
they went through in the thymus.  
 
Despite the low and varied affinities, T cells are capable of being activated 
upon binding to their cognate pMHC. Many studies have thus been done to try 
and understand how the TCR recognizes and bind to its cognate pMHC 
146,196,197. Despite many studies, no general rule for TCR binding has been 
found as each binding theory proposed has its own supporting and disproving 
evidences. However, similarities have also been observed. Most TCRs bind 
with a diagonal orientation lest a few exceptions 198,199. The Vα domain of the 
TCR resides over the α2 helix of the MHC molecule and the N-terminal of the 
peptide, whilst the Vβ domain is positioned over the α1 helix of the MHC and 
the C-terminal of the peptide 146. With a larger area of contact, the MHC 
surface dominates contact with the TCR although there are cases where the 
TCR is more peptide centric with a “superbulged” peptide 200. Next, all TCRs 
have been shown to contact their cognate pMHC ligand with their CDR loops. 
Since TCRs do not get activated binding to MHC presenting self-peptide, it 
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was proposed that contacts with the peptide should be stronger than that with 
the MHC. With that, CDR loops have been proposed to bind specifically to 
certain regions, with the germline-encoded CDR1 and CDR2 loops 
responsible for binding the MHC and the hypervariable CDR3 loop 
recognizing the peptide presented 201,202. However, this is hardly seen in actual 
TCR – pMHC complexes 203. Several examples of CDR1 and CDR2 loops 
interacting with the antigenic peptide and the CDR3 loops playing a prominent 
role contacting the MHC have also been observed 204. Thus, with more and 
more studies being done, a view where the CDR loops of the TCR are flexible 
and can adapt partially to changes in the peptide or MHC seems to be closer to 
the real scenario. 
 
Different models have also been proposed for TCR binding to pMHC. One of 
them is the two-step binding model 205. By mutating the residues on the MHC 
molecule in contact with the TCR and characterizing the binding affinities of 
the TCR thereafter, Wu et al. proposed that the TCR binds to its cognate 
pMHC in a two-step binding model, with the MHC contacts predominant in 
the initial association with the TCR and guiding the TCR docking, mainly 
independent of the peptide 205. The peptide contacts subsequently dominate 
stabilization and impart specificity, further playing a role in T cell activation 
by modulating the duration of binding. On the other hand, Gras et. al. 
compared the structures of three human TCRs binding to the HLA-B8 MHC 
presenting an EBV antigenic peptide and proposed that it is the peptide that 
acts as the molecular glue for the association and the surrounding MHC 
interactions with the TCR are for stabilizing the ligation and modulating the 
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fine specificity of the TCR for the antigen 163. Although both groups proposed 
contrasting models, the two-step binding model looked at a TCR binding to a 
Class II MHC molecule whilst Gras et. al. looked at TCRs binding to a Class I 
MHC molecule. One main difference between Class I and Class II MHC 
molecules would be their binding grooves. The ends of the binding grooves of 
Class I MHC molecules are more narrow (“closed”) as compared to that of the 
MHC Class II molecules (“open”) and thus, peptides presented by the Class I 
MHC molecule might be presented with an upward bulge, increasing the 
number of contacts with the TCR and dictating the association 206. With that, it 
further proves that TCRs seem to have a high level of adaptability when 
binding to pMHCs as seen from the various different modes of binding.   
 
Different ways of binding, more often than not, leads to different binding 
affinities. To date, TCRs have been shown to bind with a rather weak binding 
affinity (KD ~1µM-100µM) 3 with autoimmune TCRs binding with an even 
lower binding affinity (KD ~200µM) 204. This is consistent with the thymic 
selection T cells undergo as T cells expressing TCRs that bind too strongly to 
MHC expressing self-peptide will be eliminated via negative selection. Once 
the TCR contacts its pMHC, a signaling cascade occurs, activating the T cell. 
Thus, it is logical to think that how strong a TCR binds to its cognate pMHC 
can affect its activation and function. Two parameters of TCR binding, the 
dissociation constant KD, calculated as the ratio of bound complexes vs free 
TCR and pMHC, and the half-life of binding, which is proportional to the 
dissociation rate of the complex, have been proposed to determine the 
activation status of T cells. However, there is no simple correlation between 
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these parameters and T cell activation as a range of affinities and half-lives 
have been observed for activated T cells 148. The kinetic proofreading and the 
serial triggering model place huge emphasis on the dissociation rate but have 
had supporting as well as disproving evidence 148. These models have been 
discussed in detail in Chapter 2. On the other hand, KD i.e. the affinity of the 
TCR to the pMHC has also been shown to play a dominant role in influencing 
T cell activity 149,207. One example can be seen in the LC13 TCR which 
showed agonist activity with a 12.5 µM binding affinity with one pMHC but 
antagonist activity with a 132 µM interaction with another pMHC 208. Thus, 
similar to how TCR binds to their cognate pMHC, there is no simple 
correlation between either TCR binding affinity or the half-life of the complex 
with the activity of the T cell based on studies thus far.   
 
While most studies have looked at how binding affinity of the TCR affects T 
cell activation, few have went on to show how the effector functions of the T 
cells are affected. To our knowledge, how TCR affinity for antigen between 
CD8+ T cell clones of the same specificity correlate with their effector 
functions remains to be investigated. Several studies on multiple TCRs with 
the same specificity to date either have similar affinities (A6 and B7 TCRs) or 
have only looked at the structural aspects of their binding 163. Thus, we 
characterized the binding affinities of the three TCR clones against altered 
peptide ligands i.e. mutations in the cognate Rop7 peptide, to investigate 
differences in the way these three TCR clones recognize the Ld Rop7 pMHC. 
This enables us to compare the binding recognition of these three clones with 




4.2 Materials and Methods 
 
4.2.1 Surface Plasmon Resonance (SPR). The surface of a CM5 chip was first 
washed with 2 x 100 µL of (a) HCl (b) NaOH and (c) SDS. It is then activated 
with 35 µL of NHS (N-Hydroxysuccinimide) mixed with 35 µL of EDC 
(ethyl(dimethylaminopropyl) carbodiimide) for 7 minutes at a flow rate of 0.5 
µL/min. Streptavidin, mixed in immobilizing buffer (10 mM Na Acetate, pH 
5.0), was then immobilized on the chip covalently (~2000 RUs). 35 µL of 
ethanolamine was then flowed through the chip to block off excessive reactive 
groups. Next, 10 nM of biotinylated TCRs were flowed through the 
streptavidin-coated chip until ~500 RUs of TCR were immobilized on the 
chip. Binding analysis was carried out in running buffer (20 mM HEPES, 150 
mM NaCl, pH 7.4) by flowing various concentrations of pMHC through the 
chip. The equilibrium Response Unit (RUeqm) was plotted aginst the 
concentration of pMHC flowed through and the resulting curve was fitted with 
a one-site specific binding curve with the graphical software Prism. 
 
4.2.2 Structural modeling of Altered peptide ligands (APLs). The APLs, 
IPANAGRFF and IPAFAGRFF were modeled onto the Ld MHC molecule 
presenting a nine amino acid residue peptide YPNVNIHNF (PDB-ID: 1LD9) 
209 using the Rosetta backrub program (http://kortemmelab.ucsf.edu) 210. The 
figures were generated with Pymol (DeLano Sicentic Research LLC).  
 
 111	  
4.2.3 Stability assays for pMHCs. 10 µM of pMHC were mixed with the 
respective buffers before 1 µL of 25x diluted SyPro Orange dye (Molecular 
Probes S-6650) was added to a final reaction volume of 40 µL. The 
experiment was then carried out with a 7500 Fast Real Time PCR System 
(Applied Biosystems) and the samples subjected to a heating cycle from 25°C 
to 99°C with a 1% gradient using the ROX filter as a readout. The raw melt 
curves were then analyzed with the graphical software PRISM, where the first 
derivatives of the raw melt curves for each pMHC in each condition were 
generated and their respective melting points determined. Two internal 
standards, a macaque Class I MHC molecule in 100 mM Pyridine-HCl buffer 
pH 5.5 and gamma globulin in 100 mM Imidazole buffer pH 7.0 were used for 
every run to ensure the RT-PCR machine is in working order. All experiments 
were at least duplicated. 




4.3.1 Rop7c1, Rop7c2 and Rop7c3 recognize their cognate ligands differently 
 
All three TCRs bind to their cognate pMHC with different binding affinities 
(Fig. 10), indicating that they may recognize the ligand differently. To 
investigate further, we characterized the binding affinities of the three TCRs to 
H-2Ld MHC presenting peptides with single amino acid changes, which we 
will refer to as altered peptide ligands (APLs). These APLs were selected 
based on their abilities to stabilize the Ld MHC molecule using the caged-
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tetramer approach as demonstrated by Grotenbreg et. al. 
{Grotenbreg:2008ba}. The alanine in position 4 of the original Rop7 peptide, 
IPAAAGRFF, was mutated to either a phenylalanine (F) or an asparagine (N) 
to yield two APLs: IPAFAGRFF and IPANAGRFF. Similarly, we used SPR 
to characterize the binding affinities of the TCRs to the APLs. Each TCR 
clone was bound to the chip and various concentrations of APLs were then 
flowed past the chip (Fig. 32). The sensorgrams for Rop7c3 vs each of the 
APLs were not shown as it does not bind to the APLs. 
 
Figure 32. SPR sensorgrams of Rop7c1 and Rop7c2 TCR binding to APLs. Biotinylated 
Rop7c1 TCR were immonbilized on streptavidin coated CM5 chips and various 
concentrations of the APLs Ld IPAFAGRFF (A) and Ld IPANAGRFF (B) were then flowed 
through. The equilibrium Response Unit (RUeqm) at the various concentrations were noted 
for determination of their binding affnities. Similarly, various concentrations of Ld 
IPAFAGRFF (C) and Ld IPANAGRFF (D) were flowed through Rop7c2 TCR coated chips to 
yield the sensorgrams.  
 
From the SPR data, we were able to determine the binding affinities of the 
three TCR clones with the APLs. We then compared the binding affinities of 
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the three TCR clones against the cognate peptide IPAAAGRFF and the APLs, 
IPAFAGRFF and IPANAGRFF (Fig. 33). We observe that the Rop7c1 TCR 
binds weaker (KD ≈ 231 µM) to Ld IPAFAGRFF as compared to Rop7c2 TCR 
(KD ≈ 94 µM) whilst the Rop7c3 TCR does not bind at all. On the other hand, 
Rop7c1 TCR binds stronger to Ld IPANAGRFF (KD ≈ 24 µM) as compard to 
the Rop7c2 TCR (KD ≈ 46 µM). The Rop7c3 TCR similarly did not bind. 
Thus, we see a difference in heirarchy of binding affinities of the various 
clones against the different pMHCs.  
 
 
Figure 33. Equilibrium binding analysis of the TCR clones against the various pMHC 
ligands. For each TCR – pMHC pair, the RUeqm from the SPR binding studies were plotted 
against the concentration of pMHC passed through (black lines). These data were then curve 
fitted with a one-site binding model (red lines) to generate the binding affinities of each TCR 
cloen to each pMHC.  
 
For the wild type peptide IPAAAGRFF, the Rop7c1 TCR binds the strongest, 
followed by the Rop7c3 TCR and the Rop7c2 TCR binds the weakest. For 
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IPAFAGRFF, the Rop7c2 TCR binds the strongest, followed by Rop7c1 TCR 
whilst the Rop7c3 TCR does not bind at all. Lastly, for the IPANAGRFF, the 
Rop7c1 TCR binds the strongest, followed by the Rop7c2 TCR whilst the 
Rop7c3 TCR does not bind at all. If the three TCRs recognize their ligands in 
the same way, we should observe a similar hierarchy in binding affinities for 
all three different peptides i.e. Rop7c1 TCR should bind with the strongest 
affinity to all three ligands, followed by Rop7c3 TCR and lastly Rop7c2 TCR. 
However, the three TCRs bind all ligands with different hierarchy of binding 
affinities, implying that the three TCR clones recognize their ligands in a 
qualitative different manner. 
 
 
Figure 34. Models for APLs in MHC peptide binding groove. The Rosetta Backrub 
program was used to predict how the APLs IPAFAGRFF and IPANAGRFF would bind to the 
MHC binding groove in comparison to the wild-type peptide IPAAAGRFF. The IPAFAGRFF 
peptide (orange) (A) and the IPANAGRFF peptide (cyan) (B) were overlaid with the 
IPAAAGRFF peptide (green). The peptides overlaid almost perfectly except for the mutated 
residues, which were pointing upwards. The phenylalanine in IPAFAGRFF (C) and the 
asparagine in IPANAGRFF (D) are both pointing out of the MHC binding groove, implying 




To take a closer look at how the three TCR clones interact with the APLs, we 
modeled how each of the altered peptide ligand sits on the MHC. In this way, 
we will be able to see how the peptide can possibly interact with the TCR. The 
Rosetta backrub modeling program has been shown to have an improved 
accuracy of predicting point-mutant side chain conformations 210 and thus, we 
utilized it to look at the conformations of the various peptides in the MHC 
binding grove (Fig. 34).  
 
The lowest energy conformation of the IPAFAGRFF peptide (Rosetta Score: 
572.01) (orange) bound to the MHC was overlaid with the lowest energy 
conformation of the wild-type IPAAAGRFF peptide (Rosetta Score: 584.478) 
(green) (Fig. 34A). We see that there are little changes in the backbone of both 
peptide as well as their side chain conformations. However, we can clearly see 
that the mutated Phenylalanine (F) points upwards, towards the TCR. Figure 
34C clearly shows the F pointing out of the MHC peptide binding groove. 
Similarly, from the overlay of the lowest energy conformation of the 
IPANAGRFF (Rosetta score: 585.366) (cyan) peptide and the IPAAAGRFF 
(green) peptide, we observe that the mutated N is also pointing upwards with 
little changes to the backbone and the conformations of other amino acid 
residues. Figure 34D shows the N also pointing out of the peptide binding 
groove. With these models, we show that each APL presents a different 
structural landscape to the TCR clones and might explain the differences in 




4.3.2 Stabilities of the Ld MHC presenting APLs  
 
MHC molecules present peptides for T cell recognition. Class I MHC 
molecules present antigenic peptides of approximately eight to nine amino 
acid residues either cytosolic or nuclear in origin, whilst Class II MHC 
molecules present exogenously derived peptide antigens 6. Without peptides in 
their binding grooves, MHC molecules become unstable. Although we have 
shown that the APLs can bind to the MHC molecule i.e. the TCR clones could 
bind to them, it would be insightful to see if the APLs can stabilize the MHC 
molecule to the same extent as the wild-type peptide. This will enable us to 
determine if the change in binding affinities observed for each TCR clone 
against the APLs is affected by the stability of the MHC itself. To this end, we 
utilized DSC, as mentioned in Chapter 3, to compare the melting points of the 
MHC molecules. Figure 35 shows the derivative of the melt curves generated 
for the MHC presenting the wild type peptide, Ld IPAAAGRFF. Figure 35D 
shows the melting points of the pMHC across the various conditions assayed.  
 
We can see that the Ld IPAAAGRFF MHC has similar melting points across 
the buffer conditions except in buffers at pH extremities i.e. buffer condition 
1, 2, 12 and 14 (Table 4). Two conditions are omitted from the figure, namely 
Condition 13: 100mM CHES pH 9.5 and Condition 15: 100mM CAPS pH 
10.0 as the pMHC is not stable under these conditions as seen from their raw 
melt curves (not shown). 
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Figure 35. Stability assay for Ld IPAAAGRFF MHC. (A), (B) and (C) Derivatives of melt 
curves generated for the full set of buffer conditions. (D) Tm for the Ld IPAAAGRFF MHC 
across all conditions. The numbers corresponding to the conditions tested are indicated in 
Table 4. 
 
Similarly, Figure 36 and Figure 37 shows the melting points at various buffer 
conditions for Ld IPAFAGRFF and Ld IPANAGRFF respectively. The 
melting points for both APLs were also observed to be similar across all buffer 
conditions except at pH extremities (Fig. 36D and 37D). We then plotted the 
melting points of each pMHC under different buffer conditions together to 
investigate if there are any differences in their stabilities (Fig. 38) From the 
graph, we see that other than the first few conditions, the APLs, Ld 
IPANAGRFF and Ld IPAFAGRFF, have a slightly lower melting point across 
the buffer conditions as compared to Ld IPAAAGRFF. This could be due to 





Figure 36. Stability assay for Ld IPAFAGRFF MHC. (A), (B) and (C) Derivatives of melt 
curves generated for the full set of buffer conditions. (D) Tm for the Ld IPAFAGRFF MHC 
across all conditions. The numbers corresponding to the conditions tested are indicated in 
Table 4. 
 
Figure 37. Stability assay for Ld IPANAGRFF MHC. (A), (B) and (C) Derivatives of melt 
curves generated for the full set of buffer conditions. (D) Tm for the Ld IPANAGRFF MHC 
across all conditions. The numbers corresponding to the conditions tested are indicated in 
Table 4. 
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4.3.3 TCR binding affinity is not indicative of effector function 
 
As investigated in Chapter 2, all three TCR clones bind with a different 
binding affinity to their cognate pMHC ligand, Ld IPAAAGRFF, with the 
Rop7c1 TCR binding the strongest, followed by Rop7c3 TCR and the Rop7c2 
TCR with the weakest binding. In addition, as mentioned above, we have also 
shown that each TCR clone recognizes their ligands differently in a qualitative 
manner. Several hypotheses on T cell signaling have revolved around the 
strength of the binding affinities of the TCR to their ligands. However, no 




Figure 38. Comparison of Tms for all pMHCs. Tm for the Ld IPAAAGRFF MHC (black), Ld 
IPANAGRFF (blue) and Ld IPAFAGRFF (red) across all conditions indicate that the APLs 
stabilize the MHC to a weaker extent than the wild-type peptide. The numbers corresponding 
to the conditions tested are indicated in Table 4. 
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In addition, some TCRs have been shown to have agonistic activities only 
with high binding affinities but antagonistic activities if they bind with weak 
binding affinities, implying a correlation between binding affinities and 
activity 208,211. However, these studies look at binding affinities of the TCR 
with different pMHC ligands and thus, different peptides binding to the MHC 
may also be affecting T cell activity other than the TCR binding strength.  
 
In our model, we look at three TCRs recognizing the same pMHC ligand. 
Thus, changes in effector function can be solely attributable to the T cell. To 
this end, our collaborators have done a series of experiments to characterize 
the effector functions of the three TCR clones. First, they found that when T 
cells expressing specifically each TCR clone were transferred into 
Toxoplasma infected mice, they proliferated to different extents (not shown). 
Rop7c1 T cells proliferated the most, followed by Rop7c3 and lastly Rop7c2, 
in a manner similar to the hierarchy of their binding affinities. Although this 
seems to imply that their proliferation is tied to their binding affinities, it is 
also possible that these T cells may be intrinsically different in proliferation 
capability due to the TCR they express. Our collaborators then stimulated the 
T cells with plate-bound anti-CD3/anti-CD28, activating the T cells 
independent of the binding affinities of their TCRs (Fig. 39A). At a high dose 
of antibodies (5µg/ml), both Rop7c1 and Rop7c3 T cells underwent several 
rounds of replication. On the other hand, Rop7c2 T cells did not proliferate. 
When a lower dose of antibodies was used (0.5µg/ml), only Rop7c3 T cells 
proliferated. This indicated that each T cell clone have an intrinsic difference 
in proliferative capability.  
 121	  
 
Figure 39. Effector function of the three TCR clones upon activation. (A) Rop7c1, 
Rop7c2 and Rop7c3 T cells were labeled with the CFSE dye and stimulated with different 
concentrations of anti-CD3 and anti-CD28. T cell proliferation was measured by CFSE 
dilution after 5 days of stimulation. (B) Proliferation of the T cell clones was similarly 
measured by CFSE dilution but they were stimulated with different amounts of peptide-loaded 
BMDCs. (C) T cell clones were co-cultured with peptide pulsed BMDCs for 48 hours before 
the amount of cytokines in the culture supernatant were measured. (Data shared by Lee Kim 
Swee and the Hidde Ploegh Lab) 
 
They then stimulated the T cells with Rop7 peptide loaded bone marrow 
derived dendritic cells (BMDCs) and looked at their proliferation (Fig. 39B). 
All three T cell clones proliferated robustly at low T cell to dendritic cell ratio. 
However, at a higher ratio, 50 T cells to 1 dendritic cell, proliferation 
decreased for both Rop7c1 and Rop7c2. Rop7c3 T cells, on the other hand, 
proliferated robustly even with less BMDCs. This shows that the inability of 
the Rop7c2 T cells to proliferate with plate-bound anti-CD3/anti-CD28 was 
not due to the absence of co-stimulatory signals which will be provided by the 
dendritic cells. This data also supports the notion that Rop7c3 T cells might 
have a higher intrinsic capability to proliferate as compared to the other two 
clones. 
 122	  
Our collaborators also looked at the cytokine production of each clone after 
stimulation by the peptide loaded BMDCs (Fig. 39C). Rop7c3 T cells 
produced the largest amounts of effector cytokines such as IFN-γ and TNF-α, 
as well as IL-2, a cytokine required for T cell proliferation. Rop7c2 T cells, on 
the other hand, produced the least amounts of cytokines tested. This correlates 
with the level of activation and proliferation seen with the three T cell clones 
(Fig. 39A and B). Thus, factors other than TCR binding affinity seem to be 
affecting their downstream effector functions. This may explain the lack of a 
clear and simple correlation between the binding affinity of a TCR to its 





CD8+ T cells are important in resolving attacks by bacteria, viruses and 
parasites. They utilize their unique TCR to recognize the antigenic peptides 
presented by MHC molecules on infected cells. Thus, how TCRs bind to their 
cognate pMHC ligand and their binding strengths are important parameters for 
T cell activation.  
 
Here we investigated if three different TCR clones specific for the same 
pMHC ligand recognize their ligands differently. By comparing their binding 
to altered peptide ligands (APLs), we noticed that all three TCR clones 
showed varying levels of sensitivity against single amino acid mutations (Fig. 
33). This implies that each TCR clone recognizes the pMHC ligand differently 
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in a qualitative manner. A study by Gras et. al. on the crystal structures of 
three human TCRs binding to the same cognate peptide ligand (EBV epitope 
restricted by HLA-B8 MHC molecule) also showed that each TCR clone binds 
differently to the cognate pMHC 163. They then went on to propose that TCR 
binding to their cognate pMHC ligand has a peptide-centric view i.e. the 
antigenic peptide acts as the main determinant of the binding whilst the 
surrounding MHC interactions stabilize TCR ligation and modulate fine 
specificity. Although we do not have crystal structures of the Rop7 TCR 
clones and the Ld Rop7 MHC in complex, the observation that single amino 
acid changes could drastically affect binding affinities of the TCRs seem to 
support the importance of the antigenic peptide in TCR recognition.   
 
We also see that the binding affinities of the Rop7c2 TCR increase when 
binding to the APLs. The APLs have the central amino acid residue of the 
peptide changed from an alanine to that of a more bulky residue, 
phenylalanine or asparagine. This could imply that the CDR regions of the 
Rop7c2 TCR could make more contacts with the peptide and thus, bind with a 
higher binding affinity. This will also explain why it binds the weakest with 
the wild-type peptide, which consists of mostly alanine and glycine. On the 
other hand, the Rop7c1 TCR binds with a lower affinity to IPANAGRFF and 
an even lower affinity to the IPAFAGRFF. In addition, the Rop7c3 TCR 
could not bind both APLs at all. This implies that both the Rop7c1 and the 
Rop7c3 TCRs were not able to accommodate the introduction of a bulky 
residue at the centre of the peptide and can also explain their better binding 
affinities to the relatively “featureless” wild-type peptide IPAAAGRFF. 
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Crystal structures of these complexes, though difficult to obtain, can indicate 
the amino acid residues in contact and provide a clearer picture of their 
binding mechanism. This will provide insights on the recognition “patterns” 
TCRs use to recognize different type of ligands.  
 
Next, it was also noted that the APLs possess lower stabilities as compared to 
the wild-type pMHC (Fig. 38). Peptides binding to specific alleles of Class I 
MHC molecules have been shown to possess a characteristic motif with a 
preference for specific amino acid residues at two or more positions 212. These 
characteristic amino acid residues, also known as anchor residues, are buried 
within complementary binding pockets in the MHC Class I groove designated 
A to F 213. One anchor residue for the wild-type IPAAAGRFF peptide is the 
C-terminal amino acid residue and in this case, is a phenylalanine. A look at 
the model predicted also showed this residue pointing into the MHC binding 
groove (Fig. 34). In addition, studies have shown that the Ld MHC also prefers 
to bind peptides with a proline at position two, which is also found in the wild-
type Rop7 peptide and the APLs 214. Thus, the instabilities seen in the APLs 
do not seem to stem from the removal of the anchor residues. The crystal 
structure of the Ld MHC molecule, however, has shown that several bulky side 
chains exist at the mid-cleft region of its binding groove 209. The APLs has 
both an asparagine and a phenylalanine at the middle of the binding groove 
(Fig. 34). This may cause steric hindrance between the peptide and the bulky 
side chains from the MHC mid-cleft region and in turn, diminish the ability of 
the peptide to fit in properly and stabilize the MHC.  
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To date, several studies have looked at the binding affinities and kinetics of 
the TCR and their impact on T cell activity 148. However, no clear correlation 
can be drawn between these two parameters. Our collaborators have shown 
that T cells expressing each of the Rop7 specific TCRs proliferate to different 
extent upon antigen independent activation and also secrete different amounts 
of effector cytokines when activated (Fig. 39). Although our binding affinity 
studies show that each TCR clone recognizes their ligand differently in a 
qualitative manner (Fig. 33) and may account for the differences in binding 
affinitites observed, the observation that T cells expressing the Rop7c3 TCR 
proliferates the most and secretes the highest amount of cytokines but bind 
with intermediate binding affinity further implies no simple and direct 
correlation between TCR binding affinity and effector function.  
 
Could there then be other factors involved in determining the effector 
functions of each TCR clone? T cells undergo thymic selection before entering 
the periphery as naïve T cells. During selection, T cells that binds to self-
peptide MHC weakly are positively selected. Studies have shown that T cells 
which receive stronger signals from self-peptide MHC are more readily 
positively selected and thus, the mature repertoire is enriched with T cell 
clones that can bind more strongly to antigenic pMHC, responding better to 
infections 215. Recently, Persaud et. al. looked at two CD4+ T cell lines 
specific for the same Listeria monocytogenes epitope 216. Although both 
clones bound to the cognate pMHC ligand with very similar binding affinities, 
they secrete different amounts of IL-2. In addition, using the phorbol ester 
PMA and ionomycin to activate the T cells independent of their TCRs, the two 
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T cell clones also produced different amounts of IL-2, indicating that intrinsic 
factors within each clone must play a role in determining T cell activation and 
the strength of their responses. They probed further and found that the strength 
of T cell responses were proportional to the strength of signals received from 
interaction with self-peptide MHC in the periphery. Thus, it may be possible 
that the varied cytokine responses we see in the activated Rop7 TCR clones 
may also be due to intrinsic differences in the individual clones and the 
strength of signal they receive from interacting with self-peptide MHC. 
 
 To test this hypothesis, several potential experiments can be carried out. First, 
upon activation by their cognate peptide antigens, a cascade of T cell signaling 
events occurs 217. Thus, we can first investigate if there are differences in 
signaling between the three TCR clones upon activation. Upon activation, 
proximal signaling events include Ca2+ influx as inositol trisphosphate (IP3) is 
produced and it triggers Ca2+ release from the Endoplasmic Reticulum (ER). 
Another secondary messenger, diacylglycerol (DAG), also activates the 
Mitogen-Activated Protein Kinase (MAPK)/Erk pathway. Measuring the rise 
in cytosolic Ca2+ concentration as well as amounts of phosphorylated Erk 
upon stimulation with anti-CD3 antibody will allow us to compare if there are 
differences in the signaling strength for the three TCR clones during proximal 
signaling events. Persaud et. al. observed differences in the amount of 
phosphorylated Erk but not the levels of calcium influx between the two T cell 
clones, with the clone secreting more IL-2 having a higher level of 
phosphorylated Erk 216. Thus, we may also see higher levels of phosphorylated 
Erk for the Rop7c3 T cell clone as compared to the other clones. However, if 
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we observe similar amounts of cytosolic Ca2+ and phosphorylated Erk for all 
three TCR clones over the same period of time, it would imply that the 
differences in effector functions between the three Rop7 specific T cell clones 
may instead be due to signaling events more distal to activation. 
 
To look at distal signaling events, we can then stimulate the Rop7c1, Rop7c2 
and Rop7c3 T cells with Ld IPAAAGRFF MHC tetramers for a short and long 
time i.e. 2 and 20 minutes for example. We can then look at the extent and 
kinetics of protein phosphorylation for all three clones by running a SDS-
PAGE gel of the cell lysates and doing a Western blot for proteins which are 
phosphorylated. We should see differences in both the extent as well as 
kinetics of phosphorylation for the proteins in all three T cell clones. If so, this 
would indicate that distal signaling events differ between the three T cell 
clones and are responsible for the differences in effector functions observed. 
We can then proceed to investigate if this difference in responsiveness is due 
to the different levels of signaling they receive during thymic selection and 
contacting MHCs presenting self-peptide in secondary lymphoid organs as 
seen in other studies 215,216.  
 
Interactions with self-peptide MHC have been shown to be important for T 
cells in terms of survival, development as well as their peripheral functions 218-
221. Thus, it can be envisoned that T cells that barely pass positive selection in 
the thymus may have a different signaling mechanism qualitatively as 
compared to T cells which just managed to escape negative selection, as they 
contact self-peptide MHC in the periphery. By comparing the strength of 
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signals each Rop7 T cell clone receive from their interactions with self-peptide 
MHC, it enables us to understand if their differences in effector functions can 
be attributed to these signals they receive. The expression levels of CD5 on 
developing thymocytes have been shown to positively correlate with the TCR 
signal they generate when contacting self-peptide MHC in the thymus 222. 
Looking at the levels of CD5 for all three T cell clones should allow us to 
understand if there is a difference in TCR signaling strength. Based on the 
effector function of each T cell clone observed, we should expect the levels of 
CD5 to be highest in Rop7c3 T cells, followed by Rop7c1 T cells, with 
Rop7c2 T cells expressing the least amount of CD5. In addition, transgenic 
mice expressing GFP from the Nur77 locus has been shown to be able to 
upregulate GFP expression upon higher TCR stimulus 223. We can then also 
cross the individual Rop7 TCR transnuclear mice with these Nur77-GFP 
transgenic mice and the levels of GFP in these mice should reflect the strength 
of TCR signaling in each clone upon contact with self-peptide MHC 
molecules. Once again, we should expect GFP levels to be highest for the 
Rop7c3/Nur77-GFP mice.  
 
Together with the binding affinity studies carried out, these potential 
experiments may indicate that intrinsic differences within each T cell clone are 
responsible for their effector functions and are dependent on the level of 
signaling they receive by interacting with self-peptide MHC in the periphery. 
Currently, due to the weak binding affinities of TCRs binding to pMHCs, T 
cell therapies such as adoptive T cell transfer focus on creating T cells 
expressing TCRs with enhanced binding affinities and using them for transfer. 
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However, complications may arise due to the possibility that these “enhanced” 
T cells may recognize other pMHC molecules and generate unwanted immune 
responses, sometimes leading to fatal consequences 74. If signaling perceived 
by contacting self-peptide MHC plays a direct role in the effector function of 
the CD8+ T cell, as shown by Persaud et. al. for CD4+ T cells 216, it may be a 
better strategy to select T cells with higher CD5 levels instead of transducing 
them with affinity-enhanced TCRs. In addition, earlier studies have shown 
that both CD4+ and CD8+ T cells expressing TCRs with intermediate binding 
affinities to their cognate pMHC have the optimal in vivo response as 
compared to high binding affinity clones 224-226. Although these studies did not 
look at the self-peptide binding signals received by the T cell clones, it would 
appear that solely increasing the binding affinities of TCRs as a means for 
future immunotherapeutics development would not be enough. On the 















Characterization of three murine CD8+ T cell clones isolated from the peak of 
resolving a Toxoplasma gondii infection recognizing the same antigenic 
peptide MHC revealed that T cells expressing TCRs with a range of binding 
affinities are activated during an infection. Kinetic studies on their binding 
also show a range of contact times between the TCR and the pMHC molecule. 
Thus, activation of Toxoplasma specific T cells, and perhaps T cells in 
general, is not solely dependent on the strength and duration of binding of the 
TCR. Differences in binding affinities of these three clones may be attributed 
to the way they recognize their cognate ligand. Looking at their interactions 
with different APLs revealed that each of the three TCR clones recognize their 
ligands differently in a qualitative manner. We also looked at the effector 
function of each T cell clone and found that the extent of effector function do 
not correlate positively with the binding affinity of their TCRs. This suggests 
the presence of other intrinsic factors that affect the effector function of each T 
cell clone. More experiments would need to be done to validate and identify 
possible factors.  
 
With the potential use of soluble TCRs as an alternative immunoconjugate to 
monoclonal antibodies, we also sought to increase the stability of the Rop7c1 
TCR by increasing its surface charges with AvNAPSA. Although the net 
charge of the TCR could be increased to -11 and +5 from an original of -6 
without any changes to its binding avidity, there was no increase in stability 
observed. In addition, as higher charges are conferred onto the TCR, its 
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binding avidity to the cognate ligand, as well as its stability, decreases. Charge 
– charge interactions on a molecule have been shown to be important in 
stabilizing a molecule. Thus, solely increasing the net charge of a protein may 
not be sufficient to improve its stability. Other factors such as how each 
mutated residue affects interactions with other residues as well as the changes 
in free energy would also need to be taken into consideration in the design. 
We also noted that an increase in positive charges, as well as changes to the α 
chain, generally do not result in a correctly refolded TCR, suggesting that 




With the Rop7c1 TCR shown to bind specifically to cells presenting the Rop7 
antigenic peptide, we can move on to tag cytokines such as IFN-γ to the TCR 
and check if it can still specifically recognize the Ld Rop7 MHC. If so, we can 
further characterize its effects on T cell activation as well as cytotoxic effects 
on parasite infected cells. We can also test these TCR conjugates in an in vivo 
setting with Toxoplasma infected mice. In addition, we could also work on 
improving the binding affinity of the TCR, possibly by techniques such as 
phage display, and see if we can get increased binding of the TCRs to cell 
surfaces. Last, with the experiments suggested earlier, once it was shown that 
the effector function of T cell clones is dependent on the signaling they 
receive from interactions with self-peptide MHC in the periphery, we can 
move on to investigate if this is also observed in T cell clones specific for 
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Molecular Weights and p.I.s of refolded TCRs 
 
TCR Molecular Weight (kDa) p.I. 
Rop7c1 50.72 6.08 
Rop7c2 50.82 5.97 


























































































Predicted p.I.: 9.33                      Molecular weight: 29.18 kDa 
 
 
Molecular Weights and p.I.s of refolded supercharged TCRs 
 
TCR Molecular Weight (kDa) p.I. 
Rop7c1α 1β (-11) 50.64 5.42 
Rop7c1α 1β (-25) 50.55 4.73 
Rop7c1α (-16) 1β (-11) 50.63 4.74 
Rop7c1α 1β (+5) 50.74 8.23 
 
 
 
 
 
 
 
 
 
 
